WO2007041218A2 - Regulation de recepteurs du type toll sur des cellules souches - Google Patents

Regulation de recepteurs du type toll sur des cellules souches Download PDF

Info

Publication number
WO2007041218A2
WO2007041218A2 PCT/US2006/037853 US2006037853W WO2007041218A2 WO 2007041218 A2 WO2007041218 A2 WO 2007041218A2 US 2006037853 W US2006037853 W US 2006037853W WO 2007041218 A2 WO2007041218 A2 WO 2007041218A2
Authority
WO
WIPO (PCT)
Prior art keywords
cells
tlr
cell
tlr4
antagonist
Prior art date
Application number
PCT/US2006/037853
Other languages
English (en)
Other versions
WO2007041218A3 (fr
Inventor
Yoshinori Nagai
Paul W. Kincade
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Priority to AU2006297259A priority Critical patent/AU2006297259A1/en
Priority to JP2008533600A priority patent/JP2009509540A/ja
Priority to EP06825199A priority patent/EP1929032A4/fr
Priority to CA002624087A priority patent/CA2624087A1/fr
Publication of WO2007041218A2 publication Critical patent/WO2007041218A2/fr
Publication of WO2007041218A3 publication Critical patent/WO2007041218A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Definitions

  • the present invention relates generally to the fields of cell biology, developmental biology and immunology. More particularly, it concerns methods and compositions relating to the identification, stimulation and repression of stems cells that express Toll-like receptors.
  • TLRs Toll-like receptors
  • Activation via TLRs couples innate immunity with the adaptive immunity provided by lymphocytes (Iwasaki and Medzhitov, 2004).
  • DCs dendritic cells
  • ThI T helper 1
  • Cells responsible for both innate and adaptive immunity have finite lifespans and must be constantly replenished from hematopoietic stem cells (HSCs) and progenitors in bone marrow (Kondo et al, 2003).
  • HSCs have been well studied, little is known about when maturing cells in bone marrow acquire functional TLRs and whether those receptors influence hematopoietic development.
  • HSCs give rise to a series of progenitors that gradually lose differentiation options and produce cells of a given type.
  • multipotent progenitors MPP spawn common myeloid progenitors (CMP) that give rise to either megakaryocyte/erythrocyte progenitors (MEP) or granulocyte/macrophage progenitors (GMP) (Akashi et al, 2000).
  • MMP megakaryocyte/erythrocyte progenitors
  • GMP granulocyte/macrophage progenitors
  • ELP early lymphoid progenitors
  • CLP common lymphoid progenitors
  • All information available to date indicates that commitment to, and progression within, these lineages requires well studied growth and differentiation factors such as colony stimulating factors.
  • These and other extracellular cues control expression of key transcription factors such as EBF, C/EBP ⁇ and PU.l (Henderson and Calame, 1998; Rosmarin et al, 2005).
  • TLR4 recognizes bacterial lipopolysaccharide (LPS) from Gram-negative bacteria (Hoshino et al, 1999) while TLR2 recognizes peptidoglycan and lipoteichoic acid from Gram-positive bacteria (Takeuchi et al,, 1999). Effective stimulation of cells via some TLRs requires cooperation with other molecules.
  • LPS bacterial lipopolysaccharide
  • MD-2 secreted MD-2 protein is associated with the extracellular portion of TLR4, and is essential for LPS recognition (Nagai et al, 2002).
  • the RP105/MD-1 complex cooperates with TLR2 and TLR4/MD-2 to cause antibody production to microbial membranes (Nagai et al, 2005).
  • CD 14 is known to cooperate with TLR2 and the TLR4/MD-2 complex in responses to lipoproteins and LPS respectively (Yoshimura et al, 1999; Means et al, 1999).
  • TLRs require intracellular adaptor proteins for effective signaling. All TLRs except for TLR3 use the MyD 88 adaptor protein for the production of inflammatory cytokines (Takeda and Akira, 2005).
  • TLR3 and TLR4 use a MyD88-independent pathway, which is triggered by the TRIF/ TICAM adaptor critical for induction of interferon-inducible genes (Yamamoto et al, 2003; Oshiumi et al, 2003).
  • a variety of defense mechanisms are triggered when microbial/viral products engage TLRs on innate immune cells.
  • TLR2/4 are linked to macrophage phagocytosis of bacteria (Blander and Medzhitov, 2004). TLR activation via MyD88 is required for phagosome maturation (Doyle et al, 2004).
  • TLR signaling in DCs induces the expression of histocompatibility complex (MHC) and co- stimulatory molecules as well as the production of IL- 12, a key cytokine for the induction of ThI immune responses (Iwasaki and Medzhitov, 2004).
  • MHC histocompatibility complex
  • IL- 12 a key cytokine for the induction of ThI immune responses
  • a method of stimulating a hematopoietic cell comprising (i) contacting the cell with a toll-like receptor (TLR) agonist; and (ii) culturing the cell.
  • the TLR agonist may be a TLR ligand, an anti-TLR antibody, or a TLR ligand mimic.
  • the hematopoietc cell may be a multipotent progenitor (MPP) cell, and the TLR agonist may be a TLR2 or TLR4 agonist, such as PaTn 3 CSK 4 or lipopolysaccharide.
  • the stimulted MPP may differentiate into a monocyte/macrophage of the innate immune system.
  • the MPP cell may also be contacted with a co-receptor component agonist, such as one directed at CD14 or MD-2.
  • the MPP cell may be contacted with at least two TLR agonists, each directed to a distinct TLR.
  • the method may further comprising contacting the stimulated MPP cell with a non-TLR cell growth or cell differentiation factor, and optionally include further culturing.
  • the MPP cell may be isloated or characterized based on the profile LmTL-7R ⁇ c-Kit hl Sca-l + Flk-2 + .
  • the hematopoietic cell may be a common myeloid progenitor (CMP) cell, and the TLR agonist may be a TLR2 agonist, such as PaIn 3 CSK 4 .
  • the stimulated CMP cell may differentiate into a macrophage.
  • the CMP cell may also be contacted with a co-receptor component agonist, such as one directed at CD14 or MD-2.
  • the CMP cell may be contacted with at least two TLR agonists, each directed to a distinct TLR.
  • the method may further comprise contacting the stimulated CMP cell with a non- TLR cell growth or cell differentiation factor, and optionally include further culturing.
  • the CMP cell may be isolated or characterized based on the profile LinlL-7R ⁇ fc-Kit .m' Sca-1 " prior to step (i).
  • the method may further comprise isolating the CMP cell based on CD34 + Fc ⁇ R l0 .
  • the hematopoietic cell may be a granulocyte/macrophage progenitor (GMP), and the TLR agonist may be a TLR2 or TLR4 agonist, such as PaIn 3 CSK 4 or lipopolysaccharide.
  • the stimulated cell may differentiate into a monocyte/macrophage of the innate immune system.
  • the GMP cell may also be contacted with a co-receptor component agonist, such as one directed at CD 14 or
  • the GMP cell may be contacted with at least two TLR agonists, each directed to a distinct TLR.
  • the method may further comprise contacting the stimulated GMP cell with a non-TLR cell growth or cell differentiation factor, and optionally include further culturing.
  • the GMP cell may be isolated or characterized based on the profile
  • the hematopoietic cell may be a common lymphoid progenitor (CLP).
  • the TLR agonist may be a TLR2 or TLR4 agonist, such as PaIn 3 CSK 4 or lipopolysaccharide.
  • the stimulated CLP cell may differentiate into a myeloid dendritic cell.
  • the cell may also be contacted with a co-receptor component agonist, such as one directed at CD14 or MD-2.
  • the CLP cell may be contacted with at least two TLR agonists, each directed to a distinct TLR.
  • the method may further comprise contacting the stimulated CLP cell with a non-TLR cell growth or cell differentiation factor, and optionally include further culturing.
  • the CLP cell may be isolated or characterized based on the profile Lin ' IL-7Ro; + c-Kit lo Sca-l l0 .
  • the hematopoietic cell may be a hematopoietic stem cell (HSC), such as a long-term repopulating HSC (LTR-HSC).
  • HSC hematopoietic stem cell
  • LTR-HSC long-term repopulating HSC
  • the TLR agonist may be a TLR2 or TLR4 agonist, such as PaHi 3 CSK 4 or is lipopolysaccharide.
  • the stimulated HSC or LTR- HSC may be driven out of a quiescent state.
  • the HSC cell may also be contacted with a co-receptor component agonist, such as one directed at CD 14 or MD-2.
  • the HSC may be contacted with at least two TLR agonists, each directed to a distinct TLR.
  • the method may further comprise contacting a stimulated HSC with a non- TLR cell growth or cell differentiation factor, and optionally include culturing.
  • the HSC may be isolated or characterized based on the profile Lin “ IL-7Ro; " c-Kit hl Sca- l + FLK-2 ⁇
  • a method of isolating progenitor cells comprising (i) contacting a cell population with a toll-like receptor (TLR) ligand, wherein the TLR ligand is bound to a support; and (ii) isolating cells bound to the ligand.
  • the method may further comprise enrichment by cell sorting.
  • the ligand may be a TLR2 or TLR4 ligand, such as lipopolysaccharide, PaIn 3 CSK 4 , an anti-TLR2 or -TLR4 antibody.
  • the support may be a bead, a column matrix, a plate, a filter.
  • the cell may be a GMP, a CMP, a CLP, an MMP, or an HSC.
  • the progenitor cells may be 10-fold more pure, 50-fold more pure, 100-fold more pure or 1000-fold more pure than the cell population.
  • the lymphoid progenitor cell may be obtained from a patient, treated ex vivo with the agonist, and returned to the patient.
  • the TLR agonist may be a TLR2 or TLR4 agonist, such as an antibody to TLR2 or TLR4, PaHi 3 CSK 4 or lipopolysaccharide.
  • the patient may be immunocompromised or immunodeficient, and may be a human.
  • a method of protecting hematopoietic stem and primitive progenitor cells from response to ligation of toll- like receptor comprising contacting said cells with a TLR pathway antagonist.
  • the antagonist may be a soluble TLR, an anti-TLR antibody, or a soluble TLR dimerization mimic.
  • the antagonist may be an siRNA, ribozyme, morpholino oligo, or an scFv or scAb.
  • the antagonist may reduce MyD88 expression or function, such as a MAL/TIRAP antagonist.
  • the antagonist may act on an MyD88-independent pathway, such as an antagonist that acts on TRAM or TRTF.
  • the TLR pathway may be the TLR2, TLR4, or TLR9 pathway.
  • the cells may also be contacted with a co- receptor component antagonist.
  • the co-receptor component antagonist may be directed at CD14 or MD-2.
  • Two distinct TLR pathways of said cells may be inhibited.
  • the method may further comprise treating a patient in need of bone marrow or hematopoietic stem cell transplantation with said TLR pathway antagonist at the time of transplantation.
  • the method may also further comprise treating said cells ex vivo prior to transplantation to a recipient patient.
  • the method may also further comprise isolating said cells based on CD34 + prior treating said cells with said TLR pathway antagonist.
  • a method for increasing the efficiency of lymphoid cell engraftment after transplantation into a patient comprising inhibiting one or more toll-like receptor (TLR) pathways of hematopoietic stem cells through contact with a TLR pathway antagonist.
  • the cells may be obtained from said patient, treated ex vivo with said antagonist, and returned to said patient.
  • the cell may be obtained from an allogeneic donor, treated ex vivo with said antagonist, and transplanted to said patient.
  • the TLR pathway may be inhibited with a TLR2 or TLR4 antagonist.
  • the antagonist may be a soluble TLR, an anti-TLR antibody, or a soluble TLR dimerization mimic.
  • the antagonist may be an siRNA, ribozyme, morpholino oligo, or an scFv or scAb.
  • the TLR pathway may be inhibited through inhibition of MyD88 expression or through inhibition of MyD88 function, such as a MAL/TIRAP antagonist.
  • the antagonist may act on an MyD88-independent pathway, such as an antagonist that acts on TRAM or TRIF.
  • the patient may be immunocompromised or immunodeficient, may be being treated with chemotherapy, and/or may undergone an organ transplant. The patient may be being or have been administered an immunosuppressant. The patient may suffer from an autoimmune disorder, or from another disorder or disease with an autoimmune component.
  • the patient may be a human.
  • the transplantation patient may be treated in vivo with said TLR pathway antagonist at the time of transplantation.
  • the hematopoietic cell may be a multipotent progenitor (MPP) cell, a common myeloid (CMP), a granulocyte/macrophage (GMP) cell, a common lymphoid progenitor (CLP) cell, or a hematopoietic stem cell (HSC).
  • MPP multipotent progenitor
  • CMP common myeloid
  • GMP granulocyte/macrophage
  • CLP common lymphoid progenitor
  • HSC hematopoietic stem cell
  • the MPP cell may be defined in the mouse as Lin-IL-7R ⁇ "c-Kit m Sca-l + Flk-2 + .
  • the CMP cell in the mouse may be defined as LurlL ⁇ Rarc-Kit 01 Sca-1'.
  • the CMP cell in the mouse may also be defined as CD34 + Fc ⁇ Rl°.
  • the GMP cell in mice may also be defined as Lin-IL-7R ⁇ -c-Kit hi Sca-l-CD34+Fc ⁇ R hi .
  • the CLP cell in mice may be defined as Lin ⁇ IL-7R ⁇ + c-Kitl°Sca-ll 0 .
  • the HSC cell may also be defined in the mouse as Lin"
  • IL-7R ⁇ rc-Kit m Sca-l+FLK-2 Additional useful markers in the mouse are CD34 (absent on adult hematopoietic stem cells) and CD 150 (present on HSC) (Yilmaz et al, 2006).
  • Hematopoietic tissues in human contain equivalent stem and progenitor cells that have been defined with a different collection of markers. For example, they lack CD13, CD14, CD33, CD64, glycophorin A, CD19, CD3, CD8 and CD56 associated with various blood cell lineages. Cell suspensions depleted of these lineage marker positive cells (Lin) contain CD34 + CD38 ' HSC.
  • Lin CD34 + CDlO + lymphoid progenitors
  • Lin CD34 + CD38 + CD123/IL-3R ⁇ Lo CD45RA CMP
  • Lin CD34 + CD38 + CD123/IL- 3R ⁇ CD45RA ' MEP (Manz et al. , 2002).
  • FIGS. IA-B - TLRs and related molecules are expressed by hematopoietic stem/progenitor cells.
  • FIG. IA Lineage marker negative cells were enriched from bone marrow suspensions before staining with antibodies to hematopoietic subsets and TLR2, TLR4, TLR4/MD-2, or CD 14.
  • Gating and flow cytometry analysis of LKS + , GMP, CMP, MEP, or CLP were as described by Kondo and colleagues (Konda et ah, 2003). Open histograms depict staining with the appropriate isotype matched Abs. The results shown are representative of three independent experiments.
  • FIG. IA Lineage marker negative cells were enriched from bone marrow suspensions before staining with antibodies to hematopoietic subsets and TLR2, TLR4, TLR4/MD-2, or CD 14.
  • Gating and flow cytometry analysis of LKS + , GMP, CMP, MEP, or CLP were as described by K
  • FIG. 2A Left, sorted LKS + cells (10,000 cells/well) from C57BL/6 or MyD88 "A mice were cultured in the presence of FL and SCF with medium alone, LPS (10 ⁇ g/ml) or PaIn 3 CSK 4 (1 ⁇ g/ml). After 72 h in culture, cells were analyzed by flow cytometry for expression of lineage markers. Percentages indicate the frequencies of Lin + or Lin " cells.
  • FIG. 2B Expression of CD45R/B220 or myeloid cell markers (Mac-1 and/or Gr-I) on cultured cells.
  • the bar graph depicts percentages of recovered cells bearing B220, CDl lb/Mac-1 and/or Gr-I lineage markers. Data represent mean values with standard deviations from triplicate cultures ( * P ⁇ 0.001). Similar results were obtained in three independent experiments.
  • LKS + cells 10,000 cells/well
  • LPS 10 ⁇ g/ml
  • PaHi 3 CSK 4 1 ⁇ g/ml
  • FIGS. 3A-B Stem cell rich Flk-2 " cells respond to TLR ligands and enter the cell cycle.
  • FIGS. 3A-B Stem cell rich Flk-2 " cells respond to TLR ligands and enter the cell cycle.
  • FIG. 3A Left, sorted Flk-2 " or Flk-2 + LKS + cells (10,000 cells/well) were cultured with medium alone, LPS (10 ⁇ g/ml) or PaIn 3 CSK 4 (1 ⁇ g/ml).
  • Flk-2 " LKS + cells were cultured with SCF.
  • Flk-2 + LKS + cells were cultured with SCF and FL.
  • FIGS. 4A-D - Activation of TLRs through MyD88 bypasses normal differentiation cues and drives monocytes/macrophages differentiation of myeloid progenitors.
  • FIGS. 4A-D - Activation of TLRs through MyD88 bypasses normal differentiation cues and drives monocytes/macrophages differentiation of myeloid progenitors.
  • FIG. 4A Sorted LKS " cells from C57BL/6 or MyD88 " " mice were stimulated with medium alone, LPS (10 ⁇ g/ml), PaHi 3 CSK 4 (1 ⁇ g/ml), M-CSF, or GM-CSF. After 72 h in culture, cells were analyzed by flow cytometry for expression of F4/80.
  • FIG. 4B The bar graph depicts yields, i.e., numbers of F4/80 + cell recovered per input progenitor. Data represent mean values with standard deviations from triplicate cultures and the results are representative of three independent experiments ( * P ⁇ 0.005).
  • FIG. 4C Sorted LKS " cells from C57BL/6 mice were stimulated with LPS (10 ⁇ g/ml), PaIn 3 CSK 4 (1 ⁇ g/ml), M-CSF, or GM-CSF in the presence of anti-M-CSFR
  • FIG. 4D Left, sorted CMP or GMP from C57BL/6 mice were stimulated with LPS (10 ⁇ g/ml) or PaIn 3 CSK 4 (1 ⁇ g/ml). After 24 or 48 h in culture, cells were analyzed by flow cytometry for expression of F4/80. Open histograms depict staining with the isotype matched Abs for F4/80.
  • FIGS. 5A-C - TLR stimulation drives differentiation of GMP into F4/80 hi monocytes/macrophages.
  • FIG. 5A These photomicrographs were prepared with Giemsa-May-Griinwald stained cytocentrifuged slides.
  • FIGGS. 2B-C Sorted GMP were stimulated with LPS (1 ⁇ g/ml), PaIn 3 CSK 4 (100 ng/ml), M-
  • FIGS. 6A-D - TLR stimulation allows lymphoid biased progenitors to produce myeloid dendritic cells at the expense of B lymphopoiesis.
  • FIG. 6A Sorted CLP (5,000/well) from C57BL/6 or MyD88 "7" mice were stimulated in X-VIVOl 5 with medium alone, LPS (10 ⁇ g/ml) or PEm 3 CSK 4 (100 ng/ml) plus SCF, FL and IL-7. After 7 days in culture, cells were analyzed by flow cytometry for expression of CD 19 and Mac-1 (left). The bar graphs depict cell yields for CD19 + cells or Mac- 1 + cells (right) and the data represent mean values with standard deviations from triplicate cultures
  • FIG. 6B Subsets of the recovered cells described in FIG. 6A were sorted and used to prepare Giemsa stained slides.
  • FIG. 6C Cultured cells from C57BL/6 mice were also analyzed by flow cytometry for expression of Gr-I and CDlIc.
  • FIG. 6D Sorted CLP from C57BL/6 mice were cultured in the presence of SCF, FL and IL-7 with a range of concentrations of LPS or combination of recombinant mouse CD 14-Fc protein (1 ⁇ g/ml) plus LPS. After 7 days in culture, cells were analyzed by flow cytometry for expression of CD19 and Mac-1 (left). The bar graph depicts cell yields for CD19 + cells or Mac-1 + cells (right). Data represent mean values with standard deviations from triplicate cultures ( * P ⁇ 0.003). The results are representative of three independent experiments.
  • FIG. 7 Altered differentiation patterns of single lymphoid progenitors activated via TLRs. Sorted CLP were cultured in the presence of SCF, FL and IL-7 with medium alone, LPS (10 ⁇ g/ml) or PaHi 3 CSK 4 (1 ⁇ g/ml). After
  • FIGS. 8A-B LPS rapidly changes the TLR4/MD-2 complex on hematopoietic progenitors.
  • FIG. 8A Whole bone marrow cells from C57BL/6 mice were cultured with medium alone or LPS (1 ⁇ g/ml) for 1 h.
  • the cells were then harvested and stained with mAbs to TLR4/MD-2, Mac-1, lineage markers as described in Methods, and c-Kit.
  • the MTS 10 reagent is unique in detecting a conformation dependent epitope on TLR4/MD-2 (Gilliet et ah, 2002). Open histograms depict staining with the isotype matched Ab for TLR4/MD-2. The results are representative of three independent experiments. (FIG. 8B) C57BL/6 mice were intravenously or intraperitoneally injected with PBS or 100 ⁇ g LPS from E. coli.
  • mice were sacrificed, and whole bone marrow cells were harvested and stained with mAbs to TLR4/MD-2, Mac-1, lineage markers, and c-Kit. Open histograms depict staining with the isotype matched Ab for TLR4/MD-2. The results are representative of three independent experiments.
  • FIGS. 9A-B - Lin " or Lin " c-Kit + progenitors in bone marrow express TLRs and related molecules, and the density of Fc ⁇ R corresponds with TLR expression on myeloid/erythroid progenitors.
  • FIGS. 9A-B - Lin " or Lin " c-Kit + progenitors in bone marrow express TLRs and related molecules, and the density of Fc ⁇ R corresponds with TLR expression on myeloid/erythroid progenitors.
  • FIGS. 9A-B - Lin " or Lin " c-Kit + progenitors in bone marrow express TLRs and related molecules, and the density of Fc ⁇ R corresponds with TLR expression on myeloid/erythroid progenitors.
  • FIGS. 9A-B - Lin " or Lin " c-Kit + progenitors in bone marrow express TLRs and related molecules, and the density of Fc ⁇ R corresponds with TLR expression on myeloid/
  • TLR4, TLR4/MD-2, or CD 14 were analyzed by flow cytometry on Lin + , Lin " or Lin " c-Kit bone marrow cells.
  • Whole bone marrow cells from C57BL/6 mice were stained with mAbs to lineage markers as described in the Examples and c-Kit together with TLR2, TLR4, TLR4/MD-2, or CD 14.
  • Open histograms depict staining with the isotype matched Abs. The results shown are representative of two independent experiments.
  • FIG. 9B Two color flow cytometry was used to evaluate Fc ⁇ R2/3, TLR2, TLR4, TLR4/MD-2, and CD 14 expression on LKS " cells. The results shown are representative of those obtained in two independent experiments.
  • FIGS. 9B Two color flow cytometry was used to evaluate Fc ⁇ R2/3, TLR2, TLR4, TLR4/MD-2, and CD 14 expression on LKS " cells. The results shown are representative of those obtained in two independent experiments.
  • FIG. 10A-B Lin " stem/progenitor cells express the RP105/MD-1 complex.
  • FIG. 10A Expression of RP 105 and MD-I on gated populations of Lin + , Lin " or Lin " c-Kit + bone marrow cells. Whole bone marrow cells from C57BL/6 mice were stained with mAbs to lineage markers and c-Kit together with RP 105 or MD-I. Open histograms depict staining with the relevant isotype matched Abs and the results are representative of two independent experiments.
  • FIG. 10B RP105 and MD-I were analyzed on stem/progenitor cells in bone marrow using a different flow cytometer and background settings.
  • FIG. 11 A-B - TLR stimulation causes a progression of Lm + cells from LKS + cells and soluble CD14 augments the acquisition of Mac-1 and F4/80.
  • FIG. HA Sorted LKS + cells (10,000 cells/well) from C57BL/6 mice were cultured in the presence of FL and SCF with medium alone, LPS (10 ⁇ g/ml) or PaHi 3 CSK 4 (1 ⁇ g/ml). After 24 or 48 h in culture, cells were analyzed by flow cytometry for expression of lineage markers and percentages of Lm + or Lin " cells are indicated.
  • FIG. HB Left, sorted LKS + cells from C57BL/6 mice were cultured in the presence of FL and SCF with 1 ⁇ g/ml LPS
  • FIGS. 12A-B - TLR stimulation alters some lineage-associated gene patterns in Flk-2 " HSCs.
  • Sorted Flk-2 " LKS + cells from C57BL/6 mice were stimulated with medium alone, LPS (10 ⁇ g/ml) or PaIn 3 CSK 4 (1 ⁇ g/ml) in the presence of SCF. After 24 h in culture, cells were harvested and mRNAs were isolated from cultured cells. Semi-quantitative RT-PCR was carried out to amplify transcripts for the indicated genes in each population.
  • FIG. 12A The results are shown as values normalized to peak expression for each of the transcripts and actual bands are shown in (FIG. 12B).
  • FIG. 12A The results are shown as values normalized to peak expression for each of the transcripts and actual bands are shown in (FIG. 12B).
  • FIGS. 14A-B Alteration of some lineage-associated gene patterns in TLR ligated CLPs. Sorted CLP from C57BL/6 mice were stimulated with medium alone, LPS (10 ⁇ g/ml) or PaHi 3 CSK 4 (1 ⁇ g/ml) in the presence of IL-7, FL, and SCF. After 24 h in culture, cells were harvested and mRNAs were isolated from cultured cells. Semi-quantitative RT-PCR was carried out to amplify transcripts for the indicated genes in each population. (FIG. 14A) The results are shown as values normalized to peak expression for each of the transcripts and actual bands are shown in (FIG. 14B).
  • FIGS. 15A-C Dramatic alterations in B lineage, monocytes/macrophages and dendritic cells in LPS treated mice.
  • C57BL/6 mice were injected intraperitoneally with 100 ⁇ g LPS from E. coli.
  • bone marrow cells from femurs and tibiae or spleen cells were stained with mAbs to indicated markers and analyzed by flow cytometry.
  • Percentages of B22O 10 AA4.1 + (FIG. 15A), Mac- 1 + F4/80 + (FIG. 15B), or Mac- 1 + CDl Ic + (FIG. 15C) cells are indicated.
  • the graphs depict cell numbers of B22O 10 AA4.1 + (FIG. 15A), Mac-1 + F4/80 + (FIG. 15B), or Mac- 1 + CDl Ic + (FIG. 15C) cells. Data represent mean values with standard deviations from four mice and are representative of two independent experiments.
  • C57BL/6 (Ly5.1) mice were given a lethal dose of irradiation (650R x 2) and then transplanted with a total of 2 x 10 6 bone marrow cells.
  • Two of the five groups of experimental animals received a 50:50 mixture as indicated.
  • the degree of chinierism in the marrow recipients was determined by flow cytometry 3 months following transplantation.
  • FIGS. 17A-C Lymphoid biased progenitors in bone marrow of Herpes infected mice are re-directed to become dendritic cells. Bone marrow cells were harvested from mice 7 days after ocular infection with HSV-I. Lin " c-
  • Kit 1 0 Sea- 1 + IL-7R ⁇ + pro-lymphocytes/CLP were then sorted to high purity and tested for differentiation potential in serum-free, stromal cell-free cultures containing recombinant SCF, FL and IL-7. While pro-lymphocytes from control animals produced pure CD19 + lymphocytes (FIG. 17A), virtually none were present in cultures initiated with HSV-I infected progenitors (FIG. 17B). Rather, there was dramatic production of CD45R/B220 + CD 19 " CDlIc + plasmacytoid dendritic cells, as well as CD45R/B220 " CD19 " CDl Ic + CDl Ib + myeloid dendritic cells. Actual yields of each of these cell types per input progenitor are shown in the bar graphs (FIG. 17C).
  • TLRs are expressed on, and functional in, hematopoietic progenitor cells.
  • stem cell-enriched bone marrow fractions and some highly purified progenitor cells do display functional TLR2 and TLR4/MD-2.
  • the TLR4/MD-2 complex cooperates with CD 14 at the cell surface.
  • TLR signals on the progenitors require MyD88 for optimal responses to LPS and a synthetic lipopeptide. More surprising, however, was the finding that TLR ligation obviates some of the growth factors needed for differentiation of progenitors and drives them to become monocytes/macrophages.
  • lymphoid-biased progenitors were directed to a dendritic cell (DC) fate in response to TLR signals.
  • DC dendritic cell
  • Members of the TLR family may thus allow hematopoietic stem/progenitors to directly sense microbial/viral products, providing a means for boosting the innate immune system during infection.
  • Common myeloid progenitor cells may similarly be induced to form macrophages, as can granulocyte/macrophage progenitors.
  • Common lymphoid progenitor cells can be induced to form myeloid dendritics cells.
  • ligands for TLR2 PaIn 3 CSK 4
  • TLR4 LPS
  • antagonists for TLRs may prove useful in counteracting pro- inflammatory responses that can complicate systemic microbial infections, for keeping immune cells from being depleted in the face of chronic insult, and for preventing unwanted immune responses such as in autoimmunity.
  • the inventors sought to determine if inhibiting a TLR pathway would prevent a hematopoietic progenitor cell from differentiating into a mature component of the immune system, taking advantage of the observation that nearly all TLRs require the intracellular MyD 88 adaptor protein for effective signaling, hi engraftment experiments, bone marrow from MyD88 knockout mice produced more blood cells than bone marrow from mice with normal MyD88 function, indicating that the absence, of TLR pathway signaling was preserving the blood-producing cells of the transplanted bone marrow from terminal differentiation. Rather that becoming components of the immune system, the MyD88-knockout cells continued to function as blood-producing stem cells.
  • the inventors thus propose inhibiting the TLR signaling pathways of hematopoietic progenitor cells in order to maintain the cells in a pluripotent state in the presence of TLR ligands, allowing the cells to continue producing immune system cells rather than becoming immune system cells.
  • Temporary inhibition of TLR signalling in hematopoietic progenitor cells used for bone marrow transplants, for example, could thus lead to more rapid replenishment of the immune system.
  • Small molecules, soluble TLRs or antibodies that interfere with the extracellular domains of the TLRs could also be employed, preventing interaction with intracellular signaling molecules before a natural ligand binds to TLR at the cell surface of effector cells.
  • TLRs intracellular signaling molecules after ligand binding to TLRs.
  • antagonists for TLRs may prove useful in counteracting pro-inflammatory responses that can complicate systemic microbial infections, for keeping immune cells from being depleted in the face of chronic insult, and for preventing non-beneficial immune responses such as in autoimmunity.
  • the innate immune system (macrophages, neutrophils, natural killer cells and the alternative complement pathway) is an early and rapid response system to microbial infection.
  • the actions against the invading pathogens are either direct (e.g., phagocytosis and killing) or indirect through the release of cytokines or other stimulatory molecules, which trigger the adaptive immune system by activating B cells and T cells.
  • TLRs Toll-like receptors
  • Toll was originally described in Drosophila as a type I transmembrane receptor that controls dorsal-ventral polarity during embryogenesis (Stein et at 1991).
  • the 18Wheeler (18W) protein is a homolog of Drosophila Toll. Toll and 18W share the greatest similarity to each other, as well as to the cytoplasmic tail of the mammalian IL-IRl.
  • the extracellular regions of Toll and 18W contain multiple leucine-rich repeats and carboxyl-terminal cysteine-rich domains (Eldon 1994)).
  • TLRs of different species are very different: mouse TLR4 and human TLR4 are only 53% identical. Genetic studies of leucine-rich repeat structures among different individuals also revealed that polymorphisms are responsible for a different reaction on microbial challenge.
  • the intracellular part contains a cytoplasmic domain of approximately 200 amino acids that is evolutionarily conserved. This highly conserved region is known as the TIR domain (O'Neill et at, 2000).
  • the mammalian homologs of Drosophila Toll are known as TLRs.
  • TLRs mammalian homologs of Drosophila Toll
  • TLR1-TLR6 have been characterized by their distinctive expression patterns with mRNA detection assays. TLRl is expressed ubiquitously and at rather high levels. TLR2 have been known to be expressed in peripheral blood mononuclear cells, as well as in lymphoid tissue (Yang et at, 1999). TLR3 is expressed in lung, muscle, heart, brain and intestinal cells, with alternative splicing reported in pancreas and placenta. Among peripheral blood cells, TLR3 is selectively expressed in specific subsets of dendritic cells (Kadowaki et at, 2001). TLR4 was known to be expressed by monocytes/macrophages, dendritic cells, lymphocytes, the spleen and the heart.
  • TLR5 mRNA is found in peripheral blood monocytes, leukocytes, the ovary and the prostate. TLR6 expression is found in the spleen, the thymus, the ovary and the lung (Takeuchi et at, 1999). TLR mRNA is also expressed in various epithelial cells (Cario et at, 2000), suggesting a role in monitoring for invading microbes. A. Functional Roles
  • TLR2 and TLR4 are the most extensively studied members of mammalian homologs to Drosophila Toll. Both TLR2 and TLR4 require the adapter protein MyD 88 for signaling, and immunoprecipitation studies showed direct interaction of MyD88 and IRAK (Medzhitov et al, 1998). MyD88 was originally isolated and characterized as a myeloid differentiation primary response gene. MyD88 itself consists of a carboxyl-terminal TIR domain. IRAK has been shown both to interact with both MyD88 and TRAF6 (Chaudhary et al, 1998). Research has demonstrated the necessity of another cell surface molecule for
  • TLR4 signal transduction (Shimazu et al, 1999).
  • the protein MD-2 has no intracellular domain, but on co-expression with TLR4 enhances LPS sensitivity in transfection models. MD-2 cotransfection with TLR2 had no effect on LPS response. Data support a direct binding of MD-2 to LPS. This effect was independent of CD 14 or LPS-binding protein (LBP) and suggests a specific and unique role for MD-2 in LPS recognition that contributes to modulation of the proinflammatory response of effector cells (Viriyakosol et al, 2001).
  • LBP LPS-binding protein
  • TLR2 forms heterodimeric structures with other TLR members such as TLRl and TLR6.
  • TLR2 forms heterodimeric structures with other TLR members such as TLRl and TLR6.
  • Rho-type GTPase Racl also appears to be associated with TLR2-mediated signaling.
  • This alternative pathway activates a number of phosphorylated lipids, resulting in the generation of the intracellular protein kinase Akt.
  • This pathway directly activates NF- ⁇ B, independent of the phosphorylation and degradation of I- ⁇ B (Arbibe et al, 2000).
  • TLR4 is utilized by LPS and therefore is the long-sought LPS receptor (Poltorak et al, 1998; Qureshi et al, 1999).
  • LPS has been known to induce signals very similar to IL-I, and also to bind to CD 14 on macrophages.
  • CD 14 is a known PRR on the surface of monocytes/macrophages. It has been clear for many years that CD 14 has a major role for the effects of LPS on macrophages, monocytes, and neutrophils, and that CD 14 increases the sensitivity of macrophages to LPS (Schroder et al, 2000).
  • TLR4 induces the expression of the NF- ⁇ B-controlled cytokines IL-I, IL-6 and IL-8, implicating a role for this receptor in innate immunity (Medzhitov et al, 1997). Others then proved on a genetic level that TLR4 was involved in LPS signaling (Poltorak et ⁇ /., 1998).
  • RP105 was placed in the TLR family on the basis of sequence homology, and shown to form a complex with MD-I. This complex is preferentially expressed by B lineage lymphocytes, dendritic cells and macrophages (Kimoto et al, 2003). On B lymphocytes, the RP105/MD-1 complex cooperates with TLR2 and TLR4/MD-2 to cause antibody production to microbial membranes (Nagai et al, 2005). However, the RP105/MD-1 complex can be a negative regulator of TLR4 signaling on macrophages (Divanovic et al, 2005). TLR9. Another member of the mammalian TLR family is TLR9.
  • TLR9 tet al (2000) first defined the TLR9 molecule as the receptor for bacterial DNA. Abundant mRNA transcripts of TLR9 were found in many tissues, suggesting a physiological role, which was confirmed by the generation of a TLR9-/- knockout mouse strain. These animals were shown to be incapable of responding to unmethylated CpG motifs of synthetic oligonucleotides.
  • Bacterial DNA has been known as a potent immunostimulant for mammalian cells for years. Unmethylated CpG motifs are found in microbial DNA, while these sequences are relatively rare in human DNA. When these unmethylated CpG sequences are flanked by two purines on the 5' side and two pyrimidines on the 3' end of the immunostimulatory nucleic acid, sequences in bacterial DNA induce a strong proinflammatory signal for human immune effector cells (Krieg, 1999). The specific sequences that are optimally recognized by human cells are GT-C-p-G-TT, while murine cells recognize GA-C-p-G-TT (Bauer et al, 2001).
  • TLR9-DN mutants had no TNF, IL- 12, IL-6 and interferon- ⁇ response on exposure to oligonucleotides containing microbial CpG motifs (Hemmi et al, 2000).
  • TLR9 knockout mice also are refractory to lethal shock from synthetic oligonucleotides bearing unmethylated CpG motifs that normally induce rapid hypotension and lethality in wild-type mice.
  • Evidence indicates that TLR9 is expressed on in the endomsome of immune effector cells.
  • oligonucleotides immobilized on solid surfaces fail to stimulate mammalian cells, while inhibitors of cellular uptake disrupt signaling by CpG DNA. This indicates that prokaryotic DNA may need to be internalized within the endosomal compartment before initiation of the specific signaling cascade.
  • MyD88 colocalizes with tagged TLR9 at the endosomal compartment (Hemmi et al., 2000).
  • TLR5 The major ligand for TLR5 is bacterial flagellin from either Gram- positive or Gram-negative bacteria. These proteins are highly conserved among bacterial pathogens, and considerable structural homology is essential to maintain the integrity of the locomotion system of bacterial organisms. Isolated and purified flagella protein itself, or flagellin proteins expressed on the cell surface of either Gram-positive or Gram-negative bacteria, stimulate monocyte/macrophage cells in a TLR5-specific, CD14-independent manner. The TLR5 receptor thus appears to be the main route through which the immune system recognizes flagellated bacteria (Hayashi etf ⁇ Z., 2001).
  • TLR2 has been recognized as a signal transducer for numerous bacterial products.
  • TLR2 ligands include lipoteichoic acid, synthetic lipopeptides (PaIn 3 CSK 4 , MALP -2) and the yeast-derived Zymosan.
  • TLR4 signaling is primarily activated after lipid A/LPS challenge. Purified glycolipids from Treponema brennaborense, a spirochete that causes a bovine infectious disease, have been associated with TLR4- dependent signaling.
  • Ohashi et al. reported the potential first endogenous ligand for the TLR4
  • Viral particles also act as a ligand for TLR4.
  • Kurt- Jones et al. (2000) showed that the innate immune response to respiratory syncytial virus coat protein F is mediated by signaling through TLR4 and CD 14.
  • Respiratory syncytial virus infection persisted longer in the lungs of TLR4-deficient mice compared with normal mice (Haynes et al., 2001).
  • the TLR3 ligand polyinosine-polycytidylic acid (poly(LC)) is a synthetic analog of double-stranded RNA (dsRNA), a molecular pattern associated with viral infection. dsRNA is known to induce the activation of NF-kB and the production of interferon- ⁇ through distinct mechanisms that are MyD88-dependent or MyD88- independent.
  • TLR4 signaling is primarily activated after lipid A/LPS challenge.
  • Purified glycolipids from Treponema brennaborense a spirochete that causes a bovine infectious disease, have been associated with TLR4-dependent signaling.
  • Ohashi et al reported the potential first endogenous ligand for the TLR4 (Ohashi et al, 2000)
  • Other endogenous ligands include heat shock protein gp96 (Liu et al, 2003).
  • Viral particles also act as a ligand for TLR4.
  • Kurt- Jones et al. (2000) showed that the innate immune response to respiratory syncytial virus coat protein F is mediated by signaling through TLR4 and CD 14. Respiratory syncytial virus infection persisted longer in the lungs of TLR4-deficient mice compared with normal mice (Haynes et al, 2001).
  • the TLR5 ligand flagellin is the major component of the bacterial flagellar filament, which confers motility on a wide range of bacterial species.
  • Flagellin is a potent stimulator of innate immune responses in a number of eukaryotic cells and organisms, including both mammals and plants. In mammals, flagellin triggers defense TLR5-dependent responses both systemically and at epithelial surfaces. Flagellin induces the activation of NF-/cB and the production of cytokines and nitric oxide depending on the nature of the TLR5 signaling complex.
  • TLRs 7 and 8 were initially discovered as being responsive to nucleoside analogs, but more recently, the natural ligands were found to be ssRNA.
  • Imiquimod (R837), an imidazoquinoline amine analogue to guanosine, is an immune response modifier with potent indirect antiviral activity. This low molecular synthetic molecule induces the production of cytokines such as IFN-O;. Unlike R848, Imiquimod activates only TLR7 but not TLR8. Loxoribine is a guanosine analog derivatized at position N7 and C8. This L-nucleoside is a strong stimulator of the immune system but until recently the mechanisms responsible for this immunostimulatory activity was unknown.
  • loxoribine activates the innate immune system through TLR7. Similar to imiquimod, loxoribine recognition is restricted to TLR7. This activation is MyD88- dependent and leads to the induction of the transcription factor NF-/cB.
  • TLR9 is activated by specific unmethylated CpG-containing sequences in bacterial DNA or synthetic oligonucleotides (ODNs) in the endosomal compartment.
  • ODNs synthetic oligonucleotides
  • CpG motifs are present at high frequency in bacterial DNA but rare in mammalian DNA.
  • the methylation status is a crucial distinction between bacterial and mammalian DNA.
  • Unmethylated ODNs including a CpG motif can mimic the effects of bacterial DNA, inducing B-cell proliferation and activating cells of the myeloid lineage.
  • Mammalian MyD88 is an adapter protein in the signal transduction pathway mediated by interleukin-1 (IL-I) and Toll-like receptors.
  • IL-I interleukin-1
  • Toll-like receptors In Drosophila, the Toll pathway was originally characterized for its role in the dorsoventral patterning of the embryo.
  • Drosophila Myd88 messenger RNA is maternally supplied to the embryo.
  • Homozygous mutant Myd88 female flies lay dorsalized embryos that are rescued by expression of a transgenic Myd88 complementary DNA.
  • the Drosophila Myd88 mutation blocks the ventralizing activity of a gain-of-function Toll mutation.
  • Myd88 was revealed by a mutation in krapfen (kra) in a genetic screen for new maternal genes involved in embryonic pattern formation. The embryos laid by homozygous kra 56 females fail to gastrulate properly and die as hollow tubes of dorsal cuticle. This phenotype is uiidistinguishable from those caused by mutations in the dorsal group of genes. Epistasis experiments have revealed that krapfen acts between Toll and Tube. A direct interaction was detected in yeast two hybrid experiments between Krapfen and Tube, presumably mediated by the death domains present in both proteins. Tube in turn interacts with its downstream effector Pelle through death domain association. It is therefore suggested that upon Toll activation, Myd88 associates with Pelle and Tube, in an heterotrimeric complex (Charatsi, 2002).
  • the Toll pathway was identified in Drosophila on the basis of its role in dorsoventral patterning during early embryogenesis. Genetic screens have led to the identification of maternal effect genes involved in the generation, transmission and interpretation of the signals specifying dorsoventral polarity in the embryo. Loss-of- function mutations in 11 of these genes result in a common maternal-effect lethal phenotype: fertilized eggs laid by homozygous mutant females produce embryos in which all cells adopt the cell fate normally restricted to the cells on the dorsal surface of the embryo, thus resulting in hollow tubes of dorsal cuticle. Loss-of-function mutations in the twelfth gene, cactus, result in the opposite (ventralized) phenotype.
  • TLRs Toll-like receptors
  • TLRs and receptors of the interleukin-1 (IL-I) family interact with the protein MyD88 to activate the ReI transcription factor NF-kappaB, and MyD88 interacts with the Pelle- related kinases of the IRAK family. These interactions are mediated by homophilic associations involving two well-defined structural domains of MyD88: the carboxy- terminal Toll/IL-1 receptor (TIR) domain interacts with the cognate domains in the intracytoplasmic tails of the TLRs, and the amino-terminal death domain mediates interaction with the corresponding domain of IRAK.
  • TIR carboxy- terminal Toll/IL-1 receptor
  • Drosophila Myd88 differs from its mammalian counterpart by the presence of a 162 amino-acid C- terminal extension following the T]R domain that is encoded by a separate exon. Flies carrying a transposon inserted at the 5' end of this gene have an impaired response to infection (Tauszig-Delamasure, 2002).
  • Another mutant allele of Myd88 has been identified that encodes a protein devoid of its C-terminal extension. Analysis of these mutant flies reveals that Myd88 encodes a component of the dorsoventral pathway in Drosophila embryos (Kambris, 2003).
  • TIRAP TIR-domain-containing adaptor protein
  • MaI MyD88 adaptor-like
  • TLR3 and TLR4 can transmit signals for biological responses without utilization of the MyD88 adaptor protein. These are thought to be mediated by TRIF and in some cases TRAM, resulting in interferon production (O'Neill, 2005). While it is already clear that hematopoietic stem and progenitors utilize the MyD 88 adaptor protein, the alternative pathways may also be important. Thus, agonists and antagonists to these molecules may be used alone or in conjunction with MdD88 pathway inhibitors for therapeutic applications.
  • antibody is intended to refer broadly to any immunologic binding agent such as IgG, IgM, IgA, IgD and IgE.
  • IgG and/or IgM are preferred because they are the most common antibodies in the physiological situation and because they are most easily made in a laboratory setting.
  • antibody is used to refer to any antibody-like molecule that has an antigen binding region, and includes antibody fragments such as Fab', Fab, F(ab')2, single domain antibodies (DABs), Fv, scFv (single chain Fv), and the like.
  • Fab', Fab, F(ab')2, single domain antibodies (DABs), Fv, scFv (single chain Fv), and the like The techniques for preparing and using various antibody-based constructs and fragments are well known in the art. Means for preparing and characterizing antibodies are also well known in the art (see, e.g., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988; incorporated herein by reference).
  • Monoclonal antibodies (MAbs) are recognized to have certain advantages, e.g., reproducibility and large-scale production, and their use is generally preferred.
  • the invention thus provides monoclonal antibodies of the human, murine, monkey, rat, hamster, rabbit and even chicken origin
  • a polyclonal antibody is prepared by immunizing an animal with a LEE or CEE composition in accordance with the present invention and collecting antisera from that immunized animal.
  • a wide range of animal species can be used for the production of antisera.
  • the animal used for production of antisera is a rabbit, a mouse, a rat, a hamster, a guinea pig or a goat.
  • the choice of animal may be decided upon the ease of manipulation, costs or the desired amount of sera, as would be known to one of skill in the art.
  • the immunogenicity of a particular immunogen composition can be enhanced by the use of non-specific stimulators of the immune response, known as adjuvants.
  • Suitable adjuvants include all acceptable immunostimulatory compounds, such as cytokines, chemokines, cofactors, toxins,
  • Adjuvants that may be used include IL-I, IL-2, IL-4, IL-7, IL- 12, ⁇ -interferon,
  • GMCSP BCG
  • aluminum hydroxide MDP compounds, such as thur-MDP and nor- MDP
  • CGP MTP-PE
  • lipid A lipid A
  • MPL monophosphoryl lipid A
  • RIBI which contains three components extracted from bacteria, MPL, trehalose dimycolate
  • TDM cell wall skeleton
  • CWS cell wall skeleton
  • MHC antigens may even be used.
  • exemplary, often preferred adjuvants include complete Freund's adjuvant (a non-specific stimulator of the immune response containing killed Mycobacterium tuberculosis), incomplete Freund's adjuvants and aluminum hydroxide adjuvant.
  • BRM biologic response modifiers
  • CEVI 1200 mg/d
  • CYP low-dose cyclophosphamide
  • the amount of immunogen composition used in the production of polyclonal antibodies varies upon the nature of the immunogen as well as the animal used for immunization. A variety of routes can be used to administer the immunogen including but not limited to subcutaneous, intramuscular, intradermal, intraepidermal, intravenous and intraperitoneal. The production of polyclonal antibodies may be monitored by sampling blood of the immunized animal at various points following immunization.
  • a second, booster dose (e.g., provided in an injection), may also be given.
  • the process of boosting and titering is repeated until a suitable titer is achieved.
  • the immunized animal can be bled and the serum isolated and stored, and/or the animal can be used to generate MAbs.
  • the animal For production of rabbit polyclonal antibodies, the animal can be bled through an ear vein or alternatively by cardiac puncture. The removed blood is allowed to coagulate and then centrifuged to separate serum components from whole cells and blood clots.
  • the serum may be used as is for various applications or else the desired antibody fraction may be purified by well-known methods, such as affinity chromatography using another antibody, a peptide bound to a solid matrix, or by- using, e.g., protein A or protein G chromatography.
  • MAbs may be readily prepared through use of well-known techniques, such as those exemplified in U.S. Patent 4,196,265, incorporated herein by reference.
  • this technique involves immunizing a suitable animal with a selected immunogen composition, e.g., a purified or partially purified protein, polypeptide, peptide or domain, be it a wild-type or mutant composition.
  • a selected immunogen composition e.g., a purified or partially purified protein, polypeptide, peptide or domain, be it a wild-type or mutant composition.
  • the immunizing composition is administered in a manner effective to stimulate antibody producing cells.
  • the methods for generating monoclonal antibodies generally begin along the same lines as those for preparing polyclonal antibodies. Rodents sixch as mice and rats are preferred animals, however, the use of rabbit, sheep or frog cells is also possible. The use of rats may provide certain advantages (Goding, 1986, pp. 60-61), but mice are preferred, with the BALB/c mouse being most preferred as this is most routinely used and generally gives a higher percentage of stable fusions.
  • the animals are injected with antigen, generally as described above.
  • the antigen may be mixed with adjuvant, such as Freund's complete or incomplete adjuvant.
  • adjuvant such as Freund's complete or incomplete adjuvant.
  • Booster administrations with the same antigen or DNA encoding the antigen would occur at approximately two-week intervals.
  • somatic cells with the potential for producing antibodies, specifically B lymphocytes (B cells), are selected for use in the MAb generating protocol.
  • B cells B lymphocytes
  • These cells may be obtained from biopsied spleens, tonsils or lymph nodes, or from a peripheral blood sample. Spleen cells and peripheral blood cells are preferred, the former because they are a rich source of antibody-producing cells that are in the dividing plasmablast stage, and the latter because peripheral blood is easily accessible.
  • a panel of animals will have been immunized and the spleen of an animal with the highest antibody titer will be removed and the spleen lymphocytes obtained by homogenizing the spleen with a syringe.
  • a spleen from an immunized mouse contains approximately 5 x 10 7 to 2 x 10 8 lymphocytes.
  • the antibody-producing B lymphocytes from the immunized animal are then fused with cells of an immortal myeloma cell, generally one of the same species as the animal that was immunized.
  • Myeloma cell lines suited for use in hybridoma-producing fusion procedures preferably are non-antibody-producing, have high fusion efficiency, and enzyme deficiencies that render then incapable of growing in certain selective media which support the growth of only the desired fused cells (hybridomas).
  • any one of a number of myeloma cells may be used, as are known to those of skill in the art (Goding, 1986; Campbell, 1984).
  • the immunized animal is a mouse
  • rats one may use R210.RCY3, Y3-Ag 1.2.3, IR983F and 4B210; and U-266, GM1500-GRG2, LICR-LON-HMy2 and UC729-6 are all useful in connection with human cell fusions.
  • NS-I myeloma cell line also termed P3-NS-l-Ag4-l
  • Another mouse myeloma cell line that may be used is the 8-azaguanine-resistant mouse murine myeloma SP2/0 non-producer cell line.
  • Methods for generating hybrids of antibody-producing spleen or lymph node cells and myeloma cells usually comprise mixing somatic cells with myeloma cells in a 2:1 proportion, though the proportion may vary from about 20:1 to about 1:1, respectively, in the presence of an agent or agents (chemical or electrical) that promote the fusion of cell membranes.
  • Fusion methods using Sendai virus have been described by Kohler and Milstein (1975; 1976), and those using polyethylene glycol (PEG), such as 37% (v/v) PEG, by Gefter et ⁇ /. (1977).
  • PEG polyethylene glycol
  • the use of electrically induced fusion methods is also appropriate (Goding, 1986).
  • Fusion procedures usually produce viable hybrids at low frequencies, about 1 x 10-6 to 1 x 10-8. However, this does not pose a problem, as the viable, fused hybrids are differentiated from the parental, unfused cells (particularly the unfused myeloma cells that would normally continue to divide indefinitely) by culturing in a selective medium.
  • the selective medium is generally one that contains an agent that blocks the de novo synthesis of nucleotides in the tissue culture media.
  • Exemplary and preferred agents are aminopterin, methotrexate, and azaserine. Aminopterin and methotrexate block de novo synthesis of both purines and pyrimidines, whereas azaserine blocks only purine synthesis.
  • the media is supplemented with hypoxanthine and thymidine as a source of nucleotides (HAT medium).
  • HAT medium a source of nucleotides
  • azaserine the media is supplemented with hypoxanthine.
  • the preferred selection medium is HAT. Only cells capable of operating nucleotide salvage pathways are able to survive in HAT medium.
  • the myeloma cells are defective in key enzymes of the salvage pathway, e.g., hypoxanthine phosphoribosyl transferase (HPRT), and they cannot survive.
  • HPRT hypoxanthine phosphoribosyl transferase
  • the B cells can operate this pathway, but they have a limited life span in culture and generally die within about two weeks. Therefore, the only cells that can survive in the selective media are those hybrids formed from myeloma and B cells.
  • This culturing provides a population of hybridomas from which specific hybridomas are selected.
  • selection of hybridomas is performed by culturing the cells by single-clone dilution in microtiter plates, followed by testing the individual clonal supernatants (after about two to three weeks) for the desired reactivity.
  • the assay should be sensitive, simple and rapid, such as radioimmunoassays, enzyme immunoassays, cytotoxicity assays, plaque assays, dot immunobinding assays, and the like.
  • the selected hybridomas would then be serially diluted and cloned into individual antibody-producing cell lines, which clones can then be propagated indefinitely to provide MAbs.
  • the cell lines may be exploited for MAb production in two basic ways.
  • a sample of the hybridoma can be injected (often into the peritoneal cavity) into a histocompatible animal of the type that was used to provide the somatic and myeloma cells for the original fusion (e.g., a syngeneic mouse).
  • the animals are primed with a hydrocarbon, especially oils such as pristane (tetramethylpentadecane) prior to injection.
  • the injected animal develops tumors secreting the specific monoclonal antibody produced by the fused cell hybrid.
  • the body fluids of the animal such as serum or ascites fluid, can then be tapped to provide MAbs in high concentration.
  • the individual cell lines could be cultured in vitro, where the MAbs are naturally secreted into the culture medium from which they can be readily obtained in high concentrations.
  • MAbs produced by either means may be further purified, if desired, using filtration, centrifugation and various chromatographic methods such as HPLC or affinity chromatography.
  • Fragments of the monoclonal antibodies of the invention can be obtained from the monoclonal antibodies so produced by methods which include digestion with enzymes, such as pepsin or papain, and/or by cleavage of disulfide bonds by chemical reduction.
  • monoclonal antibody fragments encompassed by the present invention can be synthesized using an automated peptide synthesizer.
  • a molecular cloning approach may be used to generate monoclonals.
  • combinatorial immunoglobulin phagemid libraries are prepared from RNA isolated from the spleen of the immunized animal, and phagemids expressing appropriate antibodies are selected by panning using cells expressing the antigen and control cells.
  • LEEs or CEEs can be used to produce antigens in vitro with a cell free system. These can be used as targets for scanning single chain antibody libraries. This would enable many different antibodies to be identified very quickly without the use of animals.
  • monoclonal antibody fragments encompassed by the present invention can be synthesized using an automated peptide synthesizer, or by expression of full-length gene or of gene fragments in E. coli .
  • the instant invention provides for the use of antibodies against various target antigens, including TLRs, which are generally of the monoclonal type, and that may be linked to at least one agent to form an antibody conjugate. It is conventional to link or covalently bind or complex at least one desired molecule or moiety. Such a molecule or moiety may be, but is not limited to a reporter molecule.
  • a reporter molecule is defined as any moiety which may be detected using an assay.
  • Non- limiting examples of reporter molecules which have been conjugated to antibodies include enzymes, radiolabels, haptens, fluorescent labels, phosphorescent molecules, chemiluminescent molecules, chromophores, luminescent molecules, photoaffmity molecules, colored particles or ligands, such as biotin.
  • Any antibody of sufficient selectivity, specificity or affinity may be employed as the basis for an antibody conjugate. Such properties may be evaluated using conventional immunological screening methodology known to those of skill in the art.
  • Sites for binding to biological active molecules in the antibody molecule include sites that reside in the variable domain that can bind pathogens, B-cell superantigens, the T cell co-receptor CD4 and the HIV-I envelope (Sasso et al, 1989; Shorki et al, 1991; Silvermann et al, 1995; Cleary et al, 1994; Lenert et al, 1990; Berberian et al, 1993; Kreier et al, 1991).
  • the variable domain is involved in antibody self-binding (Kang et al, 1988), and contains epitopes (idiotopes) recognized by anti-antibodies (Kohler et al, 1989).
  • antibody conjugates are those conjugates in which the antibody is linked to a detectable label.
  • Detectable labels are compounds and/or elements that can be detected due to their specific functional properties, and/or chemical characteristics, the use of which allows the antibody to which they are attached to be detected, and/or further quantified if desired.
  • Many appropriate imaging agents are known in the art, as are methods for their attachment to antibodies (see, for e.g., U.S. Patents 5,021,236; 4,938,948; and
  • the imaging moieties used can be paramagnetic ions; radioactive isotopes; fluorochromes; NMR-detectable substances; X-ray imaging.
  • ions such as chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), vanadium (II), terbium (III), dysprosium (III), holmium (III) and/or erbium (III), with gadolinium being particularly preferred.
  • Ions useful in other contexts, such as X-ray imaging include but are not limited to lanthanum (III), gold (III), lead (II), and especially bismuth (III).
  • radioactive isotopes for therapeutic and/or diagnostic application, one might employ, for example, 211 astatine, 14 carbon, 51 chromium, 36 chlorine, 57 cobalt, 58 cobalt, copper 67 , 152 Eu, gallium 67 , 3 hydrogen, iodine 123 , iodine 125 , iodine 131 , indium 111 , 59 iron, 32 phosphoras, rhenium 186 , rhenium 188 , 75 selenium, 35 sulphur, 9 " ⁇ technicium and/or 90 yttrium.
  • Radioactively labeled monoclonal antibodies of the present invention may be produced according to well-known methods in the art. For instance, monoclonal antibodies can be iodinated by contact with sodium and/or potassium iodide and a chemical oxidizing agent such as sodium hypochlorite, or an enzymatic oxidizing agent, such as lactoperoxidase.
  • Monoclonal antibodies according to the invention may be labeled with technetium 99 " 1 by ligaiid exchange process, for example, by reducing pertechnate with stannous solution, chelating the reduced technetium onto a Sephadex column and applying the antibody to this column.
  • direct labeling techniques may be used, e.g., by incubating pertechnate, a reducing agent such as SNCl 2 , a buffer solution such as sodium-potassium phthalate solution, and the antibody.
  • Intermediary functional groups which are often used to bind radioisotopes which exist as metallic ions to antibody are diethylenetriaminepentaacetic acid (DTPA) or ethylene diaminetetracetic acid (EDTA).
  • DTPA diethylenetriaminepentaacetic acid
  • EDTA ethylene diaminetetracetic acid
  • fluorescent labels contemplated for use as conjugates include Alexa 350, Alexa 430, AMCA, BODIPY 630/650, BODIPY 650/665, BODIPY-FL, BODIPY-R6G, BODIPY-TMR, BODIPY-TRX, Cascade Blue, Cy3, Cy5,6-FAM, Fluorescein Isothiocyanate, HEX, 6-JOE, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, REG, Rhodamine Green, Rhodamine Red, Renographin, ROX, TAMRA, TET, Tetramethylrhodamine, and/or Texas Red.
  • Another type of antibody conjugate contemplated in the present invention are those intended primarily for use in vitro, where the antibody is linked to a secondary binding ligand and/or to an enzyme (an enzyme tag) that will generate a colored product upon contact with a chromogenic substrate.
  • suitable enzymes include urease, alkaline phosphatase, (horseradish) hydrogen peroxidase or glucose oxidase.
  • Preferred secondary binding ligands are biotin and/or avidin and streptavidin compounds. The use of such labels is well known to those of skill in the art and are described, for example, in U.S. Patents 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149 and 4,366,241; each incorporated herein by reference.
  • the compound of interest may be joined to an antibody via a biologically-releasable bond, such as a selectively-cleavable linker or amino acid sequence.
  • a biologically-releasable bond such as a selectively-cleavable linker or amino acid sequence.
  • Certain linkers will generally be preferred over other linkers, based on differing pharmacologic characteristics and capabilities. For example, linkers that contain a disulfide bond that is sterically "hindered” are to be preferred, due to their greater stability in vivo, thus preventing release of the moiety prior to binding at the site of action.
  • any other linking/coupling agents and/or mechanisms known to those of skill in the art can be used to combine to components or agents with antibodies of the present invention, such as, for example, avidin biotin linkages, amide linkages, ester linkages, thioester linkages, ether linkages, thioether linkages, phosphoester linkages, phosphoramide linkages, anhydride linkages, disulfide linkages, ionic and hydrophobic interactions, or combinations thereof.
  • Cross-linking reagents are used to form molecular bridges that tie together functional groups of two different molecules, e.g., a stablizing and coagulating agent.
  • a stablizing and coagulating agent e.g., a stablizing and coagulating agent.
  • dimers or multimers of the same analog can be made or that heteromeric complexes comprised of different analogs can be created.
  • hetero-bifunctional cross-linkers can be used that eliminate unwanted homopolymer formation.
  • U.S. Patent 4,680,3308 describes bifunctional linkers useful for producing conjugates of ligands with amine-containing polymers and/or proteins, especially for forming antibody conjugates with chelators, drugs, enzymes, detectable labels and the like.
  • U.S. Patents 5,141,648 and 5,563,250 disclose cleavable conjugates containing a labile bond that is cleavable under a variety of mild conditions. This linker is particularly useful in that the agent of interest may be bonded directly to the linker, with cleavage resulting in release of the active agent.
  • Preferred uses include adding a free amino or free sulfhydryl group to a protein, such as an antibody, or a drug.
  • U.S. Patent 5,856,456 provides peptide linkers for use in connecting polypeptide constituents to make fusion proteins, e.g., single-chain antibodies.
  • the linker is up to about 50 amino acids in length, contains at least one occurrence of a charged amino acid (preferably arginine or lysine) followed by a proline, and is characterized by greater stability and reduced aggregation.
  • U.S. Patent 5,880,270 discloses aminooxy-containing linkers useful in a variety of immunodiagnostic and separative techniques.
  • Molecules containing azido groups may also be used to form covalent bonds to proteins through reactive nitrene intermediates that are generated by low intensity ultraviolet light (Potter & Haley, 1983).
  • 2- and 8-azido analogues of purine nucleotides have been used as site-directed photoprobes to identify nucleotide binding proteins in crude cell extracts (Owens & Haley, 1987; Atherton et ai, 1985).
  • the 2- and 8-azido nucleotides have also been used to map nucleotide binding domains of purified proteins (Khatoon et ah, 1989; King et ah, 1989; and Dholakia et ah, 1989) and may be used as antibody binding agents.
  • Some attachment methods involve the use of a metal chelate complex employing, for example, an organic chelating agent such as diethylenetriaminepentaacetic acid anhydride (DTPA); ethylenetriarninetetraacetic acid; N-chloro-p-toluenesulfonamide; and/or tetrachloro-3 ⁇ -6 ⁇ -diphenylglycouril-3 attached to the antibody (U.S. Patents 4,472,509 and 4,938,948, each incorporated herein by reference).
  • a coupling agent such as glutaraldehyde or periodate.
  • Conjugates with ⁇ uorescem markers are prepared in the presence of these coupling agents or by reaction with an isothiocyanate.
  • imaging of breast tumors is achieved using monoclonal antibodies and the detectable imaging moieties are bound to the antibody using linkers such as methyl-p-hydroxybenzimidate or N- succinimidyl-3 -(4-hydroxyphenyl)propionate.
  • derivatization of immunoglobulins by selectively introducing sulfhydryl groups in the Fc region of an immunoglobulin, using reaction conditions that do not alter the antibody combining site are contemplated.
  • Antibody conjugates produced according to this methodology are disclosed to exhibit improved longevity, specificity and sensitivity (U.S. Patent 5,196,066, incorporated herein by reference).
  • Site-specific attachment of effector or reporter molecules, wherein the reporter or effector molecule is conjugated to a carbohydrate residue in the Fc region have also been disclosed in the literature (O'Shannessy et al., 1987). This approach has been reported to produce diagnostically and therapeutically promising antibodies which are currently in clinical evaluation.
  • Embryonic stem cells as well as stem cells for neuronal, endothelial, cardiac and other cell types are believed by the inventors to express functional TLR. Stimulating those stem cells from a quiescent condition with TLR ligands, mimics or agonists should be beneficial in promoting tissue regeneration, remodeling and healing. They will likely need to be used in particular combinations with previously known growth and differentiation factors.
  • the following description sets forth exemplary methods of separation for hematopoietic stem cells based upon the surface expression of various markers, including TLRs and other cell surface markers.
  • FACS Fluorescence activated cell sorting
  • FACS facilitates the quantitation and/or separation of subpopulations of cells based upon surface markers.
  • Cells to be sorted are first tagged with a fluorescently labeled antibody or other marker specific ligand.
  • labeled antibodies and ligands are specific for the expression of a phenotype specific cell surface molecule.
  • the labeled cells are then passed through a laser beam and the fluorescence intensity of each cell determined.
  • the sorter distributes the positive and negative cells into label-plus and label-minus wells at a flow rate of approximately 3000 cells per second.
  • the use of multiple fluorescent tags exciting at different wavelengths allows for sorting based upon multiple or alternate criteria.
  • fluorescent labels contemplated for use as conjugates include Alexa 350, Alexa 430, AMCA, BODIPY 630/650, BODIPY 650/665, BODIPY-FL, BODIPY-R6G, BODIPY-TMR, BODIPY- TRX, Cascade Blue, Cy3, Cy5,6-FAM, Fluorescein Isothiocyanate, HEX, 6-JOE, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, REG, Rhodamine Green, Rhodamine Red, Renographin, ROX, TAMRA, TET, Tetramethyritidamine, and/or Texas Red.
  • a single PBMC sample may be analyzed with alternatively labeled anti-Ig antibody, anti-CD3 antibody, anti- CD8 antibody and anti-CD4 antibody to screen for the presence of B cells and T cells within the sample, as well as distinguishing specific T cell subsets.
  • a flow cytometer generally consists of a light source, normally a laser, collection optics, electronics and a computer to translate signals to data. Scattered and emitted fluorescent light is collected by two lenses (one positioned in front of the light source and one set at right angles) and by a series of optics, beam splitters and filters, which allow for specific bands of fluorescence to be measured.
  • Flow cytometer apparatus permit quantitative multiparameter analysis of cellular properties at rates of several thousand cells per second. These instruments provide the ability to differentiate among cell types. Data are often displayed in one- dimensional (histogram) or two-dimensional (contour plot, scatter plot) frequency distributions of measured variables.
  • the partitioning of multiparameter data files involves consecutive use of the interactive one- or two-dimensional graphics programs.
  • quantitative analysis of multiparameter flow cytometric data for rapid cell detection consists of two stages: cell class characterization and sample processing. In general, the process of cell class characterization partitions the cell feature into cells of interest and not of interest. Then, in sample processing, each cell is classified in one of the two categories according to the region in which it falls. Analysis of the class of cells is very important, as high detection performance may be expected only if an appropriate characteristic of the cells is obtained.
  • U.S. Patent 3,826,364 an apparatus which physically separates particles, such as functionally different cell types.
  • a laser provides illumination which is focused on the stream of particles by a suitable lens or lens system so that there is highly localized scatter from the particles therein.
  • high intensity source illumination is directed onto the stream of particles for the excitation of fluorescent particles in the stream.
  • Certain particles in the stream may be selectively charged and then separated by deflecting them into designated receptacles.
  • a classic form of this separation is via fluorescent tagged antibodies, which are used to mark one or more cell types for separation.
  • Micro-bead separations involve contacting a cell suspension with a slurry of microbeads labeled with a cell surface specific antibody or ligand. Cells labeled with the micro-beads are then separated using an affinity capture method specific for some property of the beads. This format facilitates both positive and negative selection.
  • Magnetic beads are uniform, superparamagnetic beads generally coated with an affinity tag such as recombinant streptavidin that will bind biotinylated immunoglobulins, or other biotinylated molecules such as, for example, peptides/proteins or lectins.
  • Magnetic beads are generally uniform micro- or nanoparticles Of Fe 3 O 4 . These particles are superparamagnetic, meaning that they are attracted to a magnetic field but retain no residual magnetism after the field is removed. Suspended superparamagnetic particles tagged to a cell of interest can be removed from a matrix using a magnetic field, but they do not agglomerate (i.e., they stay suspended) after removal of the field.
  • a common format for separations involving superparamagnetic nanoparticles is to disperse the beads within the pores of larger microparticles. These microparticles are coated with a monoclonal antibody for a cell-surface antigen. The antibody- tagged, superparamagnetic microparticles are then introduced into a cellular suspension. The particles bind to cells expressing the surface antigen of interest and maybe separated out with the application of a magnetic field. This may be facilitated by running the suspension over a high gradient magnetic separation column placed in a strong magnetic field. The magnetically labeled cells are retained in the column while non-labeled cells pass through. When the column is removed from the magnetic field, the magnetically retained cells are eluted. Both, labeled and non-labeled fractions can be completely recovered.
  • Affinity Chromatography is a chromatographic procedure that relies on the specific affinity between a substance to be isolated and a molecule that it can specifically bind to. This is a receptor-ligand type interaction.
  • the column material is synthesized by covalently coupling one of the binding partners to an insoluble matrix. The column material is then able to specifically adsorb the substance from the solution. Elution occurs by changing the conditions to those in which binding will not occur (alter pH, ionic strength, temperature, etc.).
  • the matrix should be a substance that itself does not adsorb molecules to any significant extent and that has a broad range of chemical, physical and thermal stability.
  • the ligand should be coupled in such a way as to not affect its binding properties.
  • the ligand should also provide relatively tight binding. And it should be possible to elute the substance without destroying the sample or the ligand.
  • affinity chromatography One of the most common forms of affinity chromatography is immunoaffinity chromatography. The generation of antibodies that would be suitable for use in accord with the present invention is discussed elsewhere in this document.
  • mice may be a multipotent progenitor (MPP) cell, a common myeloid (CMP), a granulocyte/macrophage (GMP) cell, a common lymphoid progenitor (CLP) cell, or a hematopoietic stem cell (HSC).
  • MPP multipotent progenitor
  • CMP common myeloid
  • GMP granulocyte/macrophage
  • CLP common lymphoid progenitor
  • HSC hematopoietic stem cell
  • the MPP cell based may be defined as Lin"IL-7R ⁇ ⁇ c-Kit hi Sca-l+Flk-2+.
  • the CMP cell may be defined as Lin-EL-7R ⁇ -c-Kit m Sca-1".
  • the CMP cell may also be defined as CD34+Fc ⁇ Rl°.
  • the GMP cell may also be defined as Lin-IL-7Ra"c-Kit n i Sca-l'CD34 + Fc ⁇ R m .
  • the CLP cell maybe defined as Lin-IL-VR ⁇ +c-Kit ⁇ Sca-l 10 .
  • the HSC cell may also be defined as Lin " IL-7R ⁇ -c-
  • Kit m Sca-l + FLK-2 Long-term HSC in adult mice has been described as Lin " Sca- I + c-Kit Hi Thy 1.1 Lo CD 15O + CD34 " Flk-2 " . Human counterparts of all of these cell types have been described. For example, human HSC are enriched among the rare fraction of Lin " CD34 + CD38 " cells in bone marrow or umbilical cord blood.
  • Stem cells are generally defined as having both the capacity to self-renew (make more stem cells by cell division) as well as being able to differentiate into mature, specialized cells.
  • a progenitor cell is an early descendant of a stem cell that can only differentiate, but it cannot renew itself anymore. In contrast, a stem cell can renew itself (make more stem cells by cell division) or it can differentiate (divide and with each cell division evolve more and more into different types of cells).
  • a progenitor cell is often more limited in the kinds of cells it can become than a stem cell. In scientific terms, it is said that progenitor cells are more differentiated than stem cells.
  • Cell culture facilitates the maintenance and propagation of cells in vitro under controlled conditions.
  • Cells may be cultured in a variety of types of vessels constructed of, for example, glass or plastic.
  • the surfaces of culture vessels may be pre-treated or coated with, for example, collagen, polylysine, or components of the extracellular matrix, to facilitate the cellular adherence.
  • Some sophisticated techniques utilize entire layers of adherent cells, feeder cells, which are used to support the growth of cells with more demanding growth requirements.
  • Cells are normally cultured under conditions designed to closely mimic those observed in vivo. In order to mimic the normal physiological environment cells are generally incubated in a CO 2 atmosphere with semi-synthetic growth media.
  • Culture media is buffered and contains, among other things, amino acids, nucleotides, salts, vitamins, and also a supplement of serum such as fetal calf serum (FCS) horse serum or even human serum. Culture media may be further supplemented with growth factors and inhibitors such as hormones, transferrin, insulin, selenium, and attachment factors.
  • FCS fetal calf serum
  • cells grown in vitro do not organize themselves into tissues. Instead, cultured cells grow as monolayers (or in some instances as multilayers) on the surface of tissue culture dishes. The cells usually multiply until they come into contact with each other to form a monolayer and stop growing when they come into contact with each other due to contact inhibition.
  • Anchorage-dependent cells show the phenomenon of adherence, i.e., they grow and multiply only if attached to the inert surface of a culture dish or another suitable support. Such cells cannot normally be grown without a solid support. Many cells do not require this solid surface and show a phenomenon known as Anchorage- independent growth. Accordingly, one variant of growing these cells in culture is the use of Spinner cultures or suspension cultures in which single cells float freely in the medium and are maintained in suspension by constant stirring or agitation. This technique is particularly useful for growing large amounts of cells in batch cultures.
  • Anchorage-independent cells are usually capable of forming colonies in semisolid media. Some techniques have been developed that can be used also to grow anchorage-dependent cells in spinner cultures. They make use of microscopically small positively-charged dextran beads to which these cells can attach.
  • the starting material for the establishment of a cell culture typically is tissue from a suitable donor obtained under sterile conditions.
  • the tissues may be minced and treated with proteolytic enzymes such as trypsin, collagenase of dispase to obtain a single cell suspension that can be used to inoculate a culture dish, hi some cases dispersion of tissue is also effectively achieved by treatment with buffers containing EDTA.
  • proteolytic enzymes such as trypsin, collagenase of dispase to obtain a single cell suspension that can be used to inoculate a culture dish, hi some cases dispersion of tissue is also effectively achieved by treatment with buffers containing EDTA.
  • a particular form of initiating a cell culture is the use of tiny pieces of tissues from which cells may grow out in vitro.
  • cells are cultured prior to contact with differentiating agents such as TLR ligands. They may also be cultured after contact, i.e., after they have been induced to differentiate toward a given or specific phenotype. Cells will be cultured under specified conditions to achieve particular types of differentiation, and provided various factors necessary to facilitate the desired differentiation.
  • differentiating agents such as TLR ligands. They may also be cultured after contact, i.e., after they have been induced to differentiate toward a given or specific phenotype. Cells will be cultured under specified conditions to achieve particular types of differentiation, and provided various factors necessary to facilitate the desired differentiation.
  • Cell growth and differentiation factors are molecules that stimulate cells to proliferate and/or promote differentiation of cell types into functionally mature forms.
  • cell growth and differentiation factors may be administered in combination with TLR ligands in order to direct the administered cells to proliferate and differentiate in a specific manner.
  • TLR ligands One of ordinary skill would recognize that the various factors may be administered prior to, concurrently with, or subsequent to the administration of TLR ligands.
  • administration of the growth and/or differentiation factors may be repeated as needed.
  • a growth and/or differentiation factor may constitute a hormone, cytokine, hematapoietin, colony stimulating factor, interleukin, interferon, growth factor, other endocrine factor or combination thereof that act as intercellular mediators.
  • intercellular mediators are lymphokines, monokines, growth factors and traditional polypeptide hormones.
  • growth factors include growth hormones such as human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH); hepatic growth factor; prostaglandin, fibroblast growth factor; prolactin; placental lactogen, OB protein; tumor necrosis factors- ⁇ and - ⁇ .; mullerian- inhibiting substance; mouse gonadotropin-associated peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors such as NGF- ⁇ ; platelet-growth factor; transforming growth factors (TGFs) such as TGF- ⁇ and TGF- ⁇ ; insulin-like growth factor-I and -II; erythropoietin (EPO
  • growth and/or differentiation factors include proteins from natural sources or from recombinant cell culture and biologically active equivalents of the native sequence, including synthetic molecules and mimetics.
  • the CD 14 antigen is a high affinity receptor for the complex of lipopolysaccharids (LPS) and LPS-Binding protein (LBP).
  • LPS lipopolysaccharids
  • LBP LPS-Binding protein
  • the CD 14 antigen is part of the functional heteromeric LPS receptor complex comprised of CD 14, TLR4 and MD-2.
  • CD 14 is strongly expressed on most human monocytes and macrophages in peripheral blood, other body fluids and various tissues, such as lymph nodes and spleen.
  • CD 14 is weakly expressed on subpopulations of human neutrophils and myeloid dendritic cells.
  • the MD-2 protein appears to associate with Toll-like receptor 4 on the cell surface and confers responsiveness to lipopolysaccyaride (LPS), thus providing a link between the receptor and LPS signaling.
  • Basic amino acid clusters in MD-2 are involved in cellular lipopolysaccharide recognition.
  • the present invention utilize soluble forms of the TLRs of the present invention, in particular, TLR2 and TLR4.
  • TLR2 and TLR4 the membrane spanning regions are removed.
  • this involves the removal of the coding regions for the membrane spanning regions.
  • an appropriate protease could be used to digest the TLR to release the receptor extracellular domain.
  • the receptor produced recombinantly or by digestion, can be purified using antibodies that bind thereto. Antibodies.
  • Another agent suitable for use in blocking TLR activation is antibody that binds to the receptor without activation as would a TLR ligand.
  • antibody is intended to refer broadly to any appropriate immunologic binding agent such as IgG, IgM, IgA, IgD and IgE.
  • IgG and/or IgM are preferred because they are the most common antibodies in the physiological situation and because they are most easily made in a laboratory setting.
  • antibody also refers to any antibody-like molecule that has an antigen binding region, and includes antibody fragments such as Fab', Fab, F(ab') 2 , single domain antibodies (DABs), Fv, scFv (single chain Fv), and the like.
  • DABs single domain antibodies
  • Fv single chain Fv
  • scFv single chain Fv
  • Monoclonal antibodies are recognized to have certain advantages, e.g., reproducibility and large-scale production, and their use is generally preferred.
  • the invention thus provides monoclonal antibodies of the human, murine, monkey, rat, hamster, rabbit and even chicken origin. Due to the ease of preparation and ready availability of reagents, murine monoclonal antibodies will often be preferred.
  • “Humanized” antibodies are also contemplated, as are chimeric antibodies from mouse, rat, or other species, bearing human constant and/or variable region domains, bispecific antibodies, recombinant and engineered antibodies and fragments thereof. Methods for the development of antibodies that are "custom-tailored” to the patient's disease are likewise known and such custom-tailored antibodies are also contemplated. Ant ⁇ sense. Antisense methodology takes advantage of the fact that nucleic acids tend to pair with "complementary" sequences. By complementary, it is meant that polynucleotides are those which are capable of base-pairing according to the standard Watson-Crick complementarity rules.
  • the larger purines will base pair with the smaller pyrimidines to form combinations of guanine paired with cytosine (G:C) and adenine paired with either thymine (A:T) in the case of DNA, or adenine paired with uracil (A:U) in the case of RNA.
  • G:C cytosine
  • A:T thymine
  • A:U uracil
  • Inclusion of less common bases such as inosine, 5-methylcytosine, 6-methyladenine, hypoxanthine and others in hybridizing sequences does not interfere with pairing.
  • ds double-stranded
  • Antisense polynucleotides when introduced into a target cell, specifically bind to their target polynucleotide and interfere with transcription, RNA processing, transport, translation and/or stability.
  • Antisense RNA constructs, or DNA encoding such antisense RNA' s may be employed to inhibit gene transcription or translation or both within a host cell, either in vitro or in vivo, such as within a host animal, including a human subject.
  • Antisense constructs may be designed to bind to the promoter and other control regions, exons, introns or even exon-intron boundaries of a gene. It is contemplated that the most effective antisense constructs will include regions complementary to intron/exon splice junctions. Thus, it is proposed that a preferred embodiment includes an antisense construct with complementarity to regions within 50-200 bases of an intron-exon splice junction. It has been observed that some exon sequences can be included in the construct without seriously affecting the target selectivity thereof. The amount of exonic material included will vary depending on the particular exon and intron sequences used. One can readily test whether too much exon DNA is included simply by testing the constructs in vitro to determine whether normal cellular function is affected or whether the expression of related genes having complementary sequences is affected.
  • complementary or “antisense” means polynucleotide sequences that are substantially complementary over their entire length and have very few base mismatches. For example, sequences of fifteen bases in length may be termed complementary when they have complementary nucleotides at thirteen or fourteen positions.- Naturally, sequences which are completely complementary will be sequences which are entirely complementary throughout their entire length and have no base mismatches. Other sequences with lower degrees of homology also are contemplated. For example, an antisense construct which has limited regions of high homology, but also contains a non-homologous region ⁇ e.g., ribozyme; see below) could be designed. These molecules, though having less than 50% homology, would bind to target sequences under appropriate conditions.
  • genomic DNA may be combined with cDNA or synthetic sequences to generate specific constructs.
  • a genomic clone will need to be used.
  • the cDNA or a synthesized polynucleotide may provide more convenient restriction sites for the remaining portion of the construct and, therefore, would be used for the rest of the sequence.
  • RNA interference also referred to as "RNA-mediated interference” or RNAi
  • RNAi Double-stranded RNA
  • dsRNA double-stranded RNA
  • dsRNA activates post-transcriptional gene expression surveillance mechanisms that appear to function to defend cells from virus infection and transposon activity (Fire et al, 1998; Grishok et al, 2000; Ketting et al, 1999; Lin and Avery et al, 1999; Montgomery et al, 1998; Sharp and Zamore, 2000; Tabara et al, 1999). Activation of these mechanisms targets mature, dsRNA- complementary niRNA for destruction.
  • RNAi offers major experimental advantages for study of gene function. These advantages include a very high specificity, ease of movement across cell membranes, and prolonged down-regulation of the targeted gene (Fire et al, 1998; Grishok et al, 2000; Ketting et al, 1999; Lin and Avery et al, 1999; Montgomery et al, 1998; Sharp et al, 1999; Sharp and Zamore, 2000; Tabara et al, 1999). Moreover, dsRNA has been shown to silence genes in a wide range of systems, including plants, protozoans, fungi, C.
  • RNAi acts post- transcriptionally, targeting RNA transcripts for degradation. It appears that both nuclear and cytoplasmic RNA can be targeted (Bosher and Labouesse, 2000). siRNAs must be designed so that they are specific and effective in suppressing the expression of the genes of interest.
  • siRNA target sequences i.e., those sequences present in the gene or genes of interest to which the siRNAs will guide the degradative machinery, are directed to avoiding sequences that may mtertere with the siRJNA's guide function while including sequences that are specific to the gene or genes.
  • siRNA target sequences of about 21 to 23 nucleotides in length are most effective. This length reflects the lengths of digestion products resulting from the processing of much longer RNAs as described above (Montgomery et al., 1998).
  • siRNAs has been mainly through direct chemical synthesis; through processing of longer, double-stranded RNAs through exposure to Drosophila embryo lysates; or through an in vitro system derived from S2 cells. Use of cell lysates or in vitro processing may further involve the subsequent isolation of the short, 21-23 nucleotide siRNAs from the lysate, etc., making the process somewhat cumbersome and expensive.
  • Chemical synthesis proceeds by making two single stranded RNA-oligomers followed by the annealing of the two single stranded oligomers into a double stranded RNA. Methods of chemical synthesis are diverse. Non-limiting examples are provided in U.S. Patents 5,889,136, 4,415,723, and 4,458,066, expressly incorporated herein by reference, and in Wincott et al (1995).
  • RNA sequences having di-nucleotide overhangs may provide the greatest level of suppression.
  • These protocols primarily use a sequence of two (2'-deoxy) thymidine nucleotides as the di-nucleotide overhangs. These dinucleotide overhangs are often written as dTdT to distinguish them from the typical nucleotides incorporated into RNA.
  • the literature has indicated that the use of dT overhangs is primarily motivated by the need to reduce the cost of the chemically synthesized RNAs. It is also suggested that the dTdT overhangs might be more stable than UU overhangs, though the data available shows only a slight ( ⁇ 20%) improvement of the dTdT overhang compared to an siRNA with a UU overhang.
  • siRNAs are found to work optimally when they are in cell culture at concentrations of 25-100 nM, but concentrations of about 100 nM have achieved effective suppression of expression in mammalian cells. siRNAs have been most effective in mammalian cell culture at about 100 nM. In several instances, however, lower concentrations of chemically synthesized siRNA have been used (Caplen, et al, 2000; Elbashir et al, 2001). WO 99/32619 and WO 01/68836 suggest that RNA for use in siRNA may be chemically or enzymatically synthesized. Both of these texts are incorporated herein in their entirety by reference.
  • RNA polymerase e.g., T3, T7, SP6
  • T3, T7, SP6 bacteriophage RNA polymerase
  • the contemplated constructs provide templates that produce RNAs that contain nucleotide sequences identical to a portion of the target gene.
  • the length of identical sequences provided by these references is at least 25 bases, and may be as many as 400 or more bases in length.
  • RNA single-stranded RNA is enzymatically synthesized from the PCR products of a DNA template, preferably a cloned cDNA template and the RNA product is a complete transcript of the cDNA, which may comprise hundreds of nucleotides.
  • WO 01/36646 incorporated herein by reference, places no limitation upon the manner in which the siRNA is synthesized, providing that the RNA may be synthesized in vitro or in vivo, using manual and/or automated procedures.
  • RNA polymerase e.g., T3, T7, SP6
  • RNA interference no distinction in the desirable properties for use in RNA interference is made between chemically or enzymatically synthesized siRNA.
  • U.S. Patent 5,795,715 reports the simultaneous transcription of two complementary DNA sequence strands in a single reaction mixture, wherein the two transcripts are immediately hybridized.
  • the templates used are preferably of between 40 and 100 base pairs, and which is equipped at each end with a promoter sequence.
  • the templates are preferably attached to a solid surface. After transcription with KJNA polymerase, the resulting dsRNA fragments may be used for detecting and/or assaying nucleic acid target sequences.
  • Ribozymes Although proteins traditionally have been used for catalysis of nucleic acids, another class of macromolecules has emerged as useful in this endeavor. Ribozymes are RNA-protein complexes that cleave nucleic acids in a site- specific fashion. Ribozymes have specific catalytic domains that possess endonuclease activity (Kim and Cook, 1987; Gerlach et al, 1987; Forster and Symons, 1987).
  • ribozymes accelerate phosphoester transfer reactions with a high degree of specificity, often cleaving only one of several phosphoesters in an oligonucleotide substrate (Cook et al, 1981; Michel and Westhof, 1990; Reinhold-Hurek and Shub, 1992).
  • This specificity has been attributed to the requirement that the substrate bind via specific base-pairing interactions to the internal guide sequence ("IGS") of the ribozyme prior to chemical reaction.
  • IGS internal guide sequence
  • Ribozyme catalysis has primarily been observed as part of sequence-specific cleavage/ligation reactions involving nucleic acids (Joyce, 1989; Cook et al, 1981).
  • U.S. Patent 5,354,855 reports that certain ribozymes can act as endonucleases with a sequence specificity greater than that of known ribonucleases and approaching that of the DNA restriction enzymes.
  • sequence-specific ribozyme-mediated inhibition of gene expression may be particularly suited to therapeutic applications (Scanlon et al, 1991; Sarver et al, 1990).
  • Morpholino oligos Morpholino oligos are so named because they are assembled from four different morpholino subunits, each of which contains one of the four bases - adenine, cytosine, guanine, and thymine - linked to a 6-membered morpholine ring.
  • Morpholino oligonucleotides are a powerful approach to loss of function analysis in Xenopus embryos. Unlike dominant negative constructs, they have the advantage of increased specificity for the particular targeted gene. VII. Methods
  • a method for stimulating hematopoietic stem cells (HSC) with Toll-like receptor (TLR) ligands, antibodies to TLR or mimics of TLR ligands is provided herein.
  • the discovery involves, in part, the observation that highly purified HSC express functional TLR.
  • Additional TLRs on HSC are presumably functional, and stimulating via single TLR or combinations of TLRs may be advantageous for directing particular stem cell responses.
  • Antibodies to TLRs or small molecules resembling TLR ligands may be used in place of bacterial/viral products to elicit desirable responses in stem cells. Agents that act downstream of these receptors on intracellular signaling pathway mediators such as MyD88, TRAM or TRIF could also be used in this fashion.
  • Another embodiment is directed to methods for stimulating myeloid progenitor cells with TLR ligands, antibodies to TLRs or mimics of TLR ligands.
  • the present inventors have discovered that highly purified progenitors can be stimulated in the absence of normal growth and differentiation factors by ligating TLR. Therefore, agonists of TLRs can be used alone, or as complementary agents with colony stimulating factors and cytokines, to stimulate or regulate blood cell formation.
  • Yet another embodiment provides for methods of directing hematopoietic stem/progenitor cells to replenish the innate immune system by stimulating them with TLR ligands.
  • Lymphoid progenitor cell are surprisingly able to be directed to become myeloid dendritic cells rather than lymphocytes when exposed to TLR ligands.
  • These dendritic cells are known to provide some aspects of innate immunity, and participate in specific, adaptive immune responses. TLR agonists can thus be used to boost production of myeloid dendritic cells, particularly in an immunodeficient or immunocompromised patient.
  • TLR antagonists to protect hematopoietic stem/progenitor cells during immunosuppression, myeloablation, bone marrow transplantation or chronic infection.
  • the inventors' findings reveal that stem cells can be depleted, exhausted, aged or otherwise harmed by unwanted stimulation via TLR.
  • a particularly useful form of this method is the maintenance of stem cell quiescence during chemotherapy. Any agent that blocks activation via TLR or downstream intracellular mediators would be protective under these circumstances.
  • Another aspect of this embodiment is preventing overproduction of cells in the innate immune system in autoimmune diseases.
  • Yet another aspect of TLR inhibition could be the protection of fetuses from intrauterine infections, as activation of fetal hematopoietic cells via TLR ligands may cause abortion or damage to the fetus.
  • the present invention also contemplates the use of TLR agonists in methods to protect hematopoietic stem/progenitor cells from differentiation into non- hematopoietic cells.
  • TLR agonists in methods to protect hematopoietic stem/progenitor cells from differentiation into non- hematopoietic cells.
  • the inventors' findings based on the discovery that early hematopoietic progenitor cells exhibit function TLRs, reveal that stem cells can be depleted, exhausted, aged or otherwise harmed by unwanted stimulation via TLR.
  • the present invention contemplates various situations where TLR antagonists will be used to protect stem cells and insure their development into hematopoietic cells, such as in the context of bone marrow regrafting following ablative chemo- or radiotherapy. Such methods will involve the use of the antagonists discussed elsewhere in this document in both in vivo and ex vivo contexts. Methods for ablative therapies are well known to those of skill in the art and can be combined, advantageously, with the stem cell protective methods of the present invention.
  • TLR ligands for administration to a host, TLR ligands, other cell surface ligands, cytokines or growth factors, soluble TLRs, antibodies, other inhibitory factors, and stimulated/differentiated cells will be suspended in a formulation suitable for administration to a host.
  • Aqueous compositions of the present invention comprise an effective amount of ligand, factor or cells dispersed in a pharmaceutically acceptable formulation and/or aqueous medium.
  • pharmaceutically and/or pharmacologically acceptable refer to compositions that do not produce an adverse, allergic and/or other untoward reaction when administered to an animal, and specifically to humans, as appropriate.
  • pharmaceutically acceptable carrier includes any solvents, dispersion media, coatings, antibacterial and/or antifungal agents, isotonic and/or absorption delaying agents and the like.
  • the use of such media or agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
  • preparations should meet sterility, pyrogenicity, general safety and/or purity standards as required by FDA Office of Biologies standards.
  • Soluble receptors, antibodies, inhibitory factors or cells, ligands, or cells for administration will generally be formulated for parenteral administration, e.g., formulated for injection via the intravenous, intramuscular, sub-cutaneous, intralesional, or even intraperitoneal routes.
  • parenteral administration e.g., formulated for injection via the intravenous, intramuscular, sub-cutaneous, intralesional, or even intraperitoneal routes.
  • the preparation of an aqueous composition that contains cells as a viable component or ingredient will be known to those of skill in the art in light of the present disclosure. In all cases the form should be sterile and must be fluid to the extent that easy syringability exists and that viability of the cells is maintained. It is generally contemplated that the majority of culture media will be removed from cells prior to administration.
  • dispersions are prepared by incorporating the various soluble receptors, antibodies, inhibitory factors, or viable cells into a sterile vehicle which contains the basic dispersion medium and the required other ingredients for maintaining cell viability as well as potentially additional components to effect proliferation or differentiation in vivo.
  • solutions Upon formulation, solutions will be administered in a manner compatible with the dosage formulation or in such amount as is therapeutically effective. Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
  • mice C57BL/6 and MyD88 " " mice were used at 8-10 weeks of age. C57BL/6 mice were purchased from the Jackson Laboratory (Bar Harbor, ME). MyD88 '7' mice were maintained in our laboratory animal resource facility (LARC) at the Oklahoma Medical Research Foundation.
  • LRC laboratory animal resource facility
  • Reagents Recombinant mouse IL-7, stem cell factor (SCF), Flt-3 ligand (FL), M-CSF, GM-CSF, recombinant mouse CD 14/Fc chimera protein, and recombinant human CD14 were purchased from R&D Systems (Minneapolis, MN). LPS from Escherichia coli 055 :B5 was purchased from Sigma- Aldrich (St. Louis, MO). A synthetic lipopeptide PaOi 3 CSK 4 was purchased from InvivoGen (San Diego, CA).
  • Abs for flow cytometry were purchased from BD Pharmingen (San Diego, CA): FITC-conjugated anti-CD2 (clone RM2-5), anti-CD3 ⁇ (clone 145- 2Cl 1), anti-CD8 ⁇ (clone 53-6.7), anti-CD45R (B220; clone RA3-6B2), anti-Ly6G (clone RB6-8C5), anti-CD l ib/Mac- 1 (clone Ml/70), anti-TER119, anti-CD34 (clone RAM34), anti-CDllc (clone HL3), PE-conjugated IL-7R ⁇ (clone SB/119), anti- CD ⁇ (clone 1D3), anti-Ly6G (clone RB6-8C5), anti-CDl lc (clone HL3), anti- Fc ⁇ R2/3 (clone 2.4G2), anti-AA4.1, anti-CD86 (clon
  • TLR4-deficient mice were intraperitoneally injected four times at a week intervals with IxIO 7 Ba/F3 cells expressing mouse TLR4 and mouse MD-2. Three days after the last injection, mice were euthanized and spleens were removed. Spleen cells were dispersed and fused with SP2/0 cells using a standard fusion protocol with polyethylene glycol 1500 (Roche, Basel, Switzerland).
  • Hybridoma cells were selected in hypoxanthine/aminopterine/thymidine medium and screened by flow cytometry with Ba/F3 cells expressing mouse TLR4/MD-2 complex and parent Ba/F3 cells. Biotin-conjugated this antibody was used for flow cytometry.
  • Bone marrow cells were harvested and enriched for lineage-negative cells by incubation with antibody to CDl lb/Mac-1
  • Serum-free, stromal cell-free cell cultures were used for these cultures. Sorted cells were cultured with X-VTVO 15 medium (Biowhittaker, Walkersville, MD) or SteniPro-34 SFM medium ( ⁇ vitrogen, Carlsbad, CA).
  • X-VIVO15 medium that seemed to be optimal for lymphoid cultures, contained 1% detoxified bovine serum albumin (Stem Cell Technologies, Vancouver, Canada), 5x10 "5 M 2-mercaptoethanol (2-ME), 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin.
  • StemPro-34 SFM medium containing 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin was usually used for myeloid cultures.
  • concentrations of cytokines were IL-7, 1 ng/ml; FL, 100 ng/ml; SCF, 20 ng/ml, M-CSF, 20 ng/ml; GM-CSF, 20 ng/ml.
  • the cells were incubated at 37°C in a humidified atmosphere of 5% CO 2 in air.
  • Single cell culture on OP9 stromal cells. Sorted CLP were cultured with X-
  • VIVO15 in the presence of SCF (20 ng/ml), FL (100 ng/ml) and IL-7 (1 ng/ml) with or without LPS (10 ⁇ g/ml), or PaIn 3 CSK 4 (1 ⁇ g/ml).
  • SCF 20 ng/ml
  • FL 100 ng/ml
  • IL-7 1 ng/ml
  • LPS 10 ⁇ g/ml
  • PaIn 3 CSK 4 (1 ⁇ g/ml
  • the conditioning medium for OP9 was MEM ⁇ medium (rnvitrogen) containing 20% FCS, 5xlO "5 M 2-ME, 2 mM L- glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin. Positive wells (more than 30 cells) were determined by microscopic observation. Cells were harvested and then stained with mAbs to CD 19, CDl Ic, and Mac-1 and analyzed by flow cytometry. Cells were also stained with rnAb to VCAM-I to exclude stromal cells. The OP9 stromal cell line was kindly provided by Dr. Shin-Ichi Hayashi (Tottori University, Japan).
  • C57BL/6 mice were intravenously or intraperitoneally injected with PBS or 100 ⁇ g LPS. After 1 h, whole bone marrow cells were harvested from femurs and tibiae, and stained with mAbs to TLR4/MD-2, Mac-1, lineage markers, and c-Kit.
  • the MTS 10 reagent is unique in detecting a conformation dependent epitope on TLR4/MD-2 (Gilliet et al, 2002).
  • RT Reverse transcriptase-PCR analysis of gene expression.
  • the mRNAs were isolated from sorted cells using MicroPoly(A) Pure (Ambion, Austin, TX). The cDNAs were then prepared from DNase I-treated mRNA using oligo-dT and Moloney murine leukemia virus reverse transcriptase (Invitrogen). PCR reactions were conducted in buffer containing 200 ⁇ M dATP, dGTP, dTTP, 100 ⁇ M dCTP and 0.5 ⁇ Ci [ ⁇ 32 P] dCTP. Aliquots were removed at cycle 25, 28 and 31 for ⁇ -actin and cycles 32, 35 and 38 for all others to insure that PCR remained within the exponential range of amplifications.
  • Toll-like receptors and associated molecules are expressed on stem cells and early hematopoietic progenitors.
  • the main aims of this study were to determine if TLRs are expressed on hematopoietic cells and whether they have a developmental role in bone marrow. Therefore, the inventors traced the expression of TLRs and their co-receptors on bone marrow cells by flow cytometry and were fortunate to have a new TLR4 specific monoclonal antibody (see Example 1).
  • An initial finding was that lineage marker negative (Lin " ), as well as Lin + cells expressed TLR2 and TLR4 as well as MD-2 and CD14 (FIG. 9A).
  • HSC and early progenitors are enriched in a Lin " c-Kit + subset. These primitive cells displayed significant amounts of TLRs and co-receptor components (FIG. 9A).
  • Lin " c-Kit + cells into five major subsets and evaluated them by flow cytometry (FIG. IA).
  • the HSC enriched Lin " IL-7R ⁇ " c-Kit hi Sea- 1 + (LKS + ) fraction had uniformly high levels of TLR2, and the same was true for Lin " IL-7R ⁇ + c-Kit l0 Sca-l l0 , pro-lymphocytes/common lymphoid progenitors (CLP).
  • CLP pro-lymphocytes/common lymphoid progenitors
  • the Lin " IL-7R ⁇ " c-Kit hl Sca-1 " (LKS " ) myeloid/erythroid progenitor fraction was heterogeneous with respect to TLR2 staining (data not shown).
  • TLR4 and CD14 were more easily seen on GMP than the two LSK " companion subsets (FIG. IA).
  • TLRs are not displayed on the cell surface so each of the above fractions was analyzed by RT-PCR (FIG. IB). In general, there was good correlation between transcript levels and flow cytometry results. Long term repopulating HSC are known to be enriched in the Flk-2 " subset of the LKS + fraction (Christensen and Weissman, 2001). Interestingly, this population had the highest levels of TLR2, TLR4, and MD- 2 mRNA, but little CD 14.
  • RP105 forms a complex with MD-I (Miyake et al, 1998; Nagai et al, 2002) and controls Ab responses to microbial membranes via TLR2 and TLR4/MD-2 (Nagai et al, 2005). It has been reported that, unlike the situation with B cells, RP 105 can be a negative regulator of TLR4 signaling on macrophages (Divanovic et al, 2005). The inventors have now found that three populations of Lin + bone marrow cells could be distinguished on the basis of densities of the RP 105/MD- 1 complex.
  • RP105/MD-1 was present on Lin “ or Lin " C-EUt + cells.
  • RP 105 was highest on CLP, detectable on GMP and near background on the other subsets.
  • the density of MD-I on most of these progenitors corresponded with RP 105 expression.
  • the inventors conclude that the most primitive of hematopoietic progenitors in bone marrow, and especially a rare stem cell enriched fraction, express TLRs and associated molecules.
  • TLR signaling drives MyD88-dependent myeloid differentiation of primitive hematopoietic cells.
  • the frequency of Lm + cells increased as a result of TLR stimulation in as little as 24 h and progressed with time (FIG. 2A and FIG. HA).
  • the dose of LPS required to stimulate hematopoietic cells under serum-free conditions was high, and the inventors found minimal responses at concentrations below 10 ⁇ g/ml (FIG. 2D).
  • Serum is known to contain soluble CD 14 that enhances LPS and TLR2 ligand recognition by mature cells (Yoshimura et al, 1999; Means et al, 1999). Therefore, the inventors added mouse CD 14-Fc protein to this culture system and found that it remarkably augmented the sensitivity of LKS + cells to LPS after 72 h (FIG. 2d and FIG. 1 IB).
  • LKS committed myeloid/erythroid progenitors would be similarly responsive. Serum-free, stromal cell free culture conditions were used to determine whether the normal cues for differentiation might be overcome. Acquisition of F4/80 was dramatic and complete in response to TLR ligands (FIG. 4A). In fact, responses at 72 h were indistinguishable from those obtained when the same population was stimulated with M-CSF. In contrast to those three differentiation stimuli, only a subset of LKS " myeloid progenitors responded to GM-CSF.
  • FIG. 4D Three subsets of LKS " cells were then sorted and stimulated with TLR ligands (FIG. 4D) to precisely identify cellular targets for TLR stimulation. MEP died in culture, regardless of stimulus, and the inventors never recovered cells expressing the erythrocyte associated TERl 19 marker (data not shown). In contrast, GMP produced F4/80 + cells within 24 h (FIG. 4D). While CMP also responded, more time was required, and the calculated yield of F4/80 + at 72 h was much less. Addition of exogenous CD 14 to this culture augmented stimulation via TLRs (data not shown), but less than that described above for stem cells.
  • myeloid progenitors representing a range of differentiation stages react to TLR ligands via a MyD88-dependent pathway under defined culture conditions and typical growth and differentiation factors are not required.
  • GMP represented the most responsive of myeloid/erythroid progenitors in bone marrow. The responses were distinct from those observed with CSFs in terms of time required and dependence on MyD88. Monocyte/macrophage subsets are rapidly produced from committed myeloid progenitors. The inventors knew if a normal range of myeloid cell types would be produced in response to TLR ligation. Accordingly, GMPs were placed in defined culture conditions for 72 h, and the recovered cells were subjected to thorough analysis (FIGS. 5 A-C).
  • LPS or PaIn 3 CSK 4 were CDllb/Mac-l + but heterogeneous with respect to densities, and this tended to correlate with the density of F4/80 (FIG. 5B).
  • the co-stimulatory CD86 molecule was present on TLR generated cells, but less than that on cells made with M-CSF. Additionally, only 9% of the cells recovered from LPS stimulated cultures displayed both Mac-1 and CDl Ic markers associated with DCs within 72 h, and none were found in any of the other cultures (data not shown).
  • TLR stimulation allows committed myeloid progenitors to differentiate into Mac-l hl F4/80 hl monocytes/macrophages with inflammatory characteristics independent of exogenous growth factors. This could represent an effective mechanism for responding to pathogens and sustaining multifunctional cells of the innate immune system.
  • TLR ligation induced production of cytokines that could then drive the differentiation observed.
  • GM-CSF and TNF ⁇ were of particular interest because they can promote the production of myeloid DCs from bone marrow in vitro (Gilliet et al, 2002).
  • TNF ⁇ can suppress B -lymphopoiesis (Sedger et al, 2002).
  • neutralizing antibodies to either GM-CSF or TNF ⁇ did not suppress the production of DCs from CLPs induced by TLR ligands (data not shown).
  • CLP express little TLR4/MD-2 or CD14 that is detectable by flow cytometry as mature B cells. Since the experiments described in FIG. 6 A were conducted with serum-free medium, exogenous CD 14 was added to the cultures to determine if this would influence efficiency of TLR4/MD-2 signals. Indeed, exogenous CD 14 dramatically augmented DC production by low doses of LPS in serum-free cultures (FIG. 6D). In contrast, exogenous CD 14 had little effect on responses to any dose of PaHi 3 CSK 4 (data not shown).
  • CLP are largely B lineage restricted when held in defined conditions, these progenitors produce DCs in stromal cell co-cultures and transplantation assays (Karsunky et al. , 2003 ; Shigematsu et al , 2004). It seemed possible that TLR ligation substitutes for that permissive signal and selects for clones that are not fully B lineage committed. Therefore, CLP were sorted to high purity and incubated for 24 h with LPS, PaHi 3 CSK 4 or medium alone. Each group of cells was then harvested, and single cells were plated on OP9 stromal cells with cytokines to assess differentiation potential (FIG. 7). Four types of clones were detected ten days later.
  • CLP produced not only pure CD19 + B lineage but also CDlIc + or CDlIc + CD19 + mixed colonies, or colonies that were CDl Ic " CDl 9 " .
  • Pure B cell colonies were the largest in this situation (data not shown).
  • Most of the CDlIc + cells were also CDl lb/Mac-r and in myeloid DC or mixed colonies were very small (data not shown).
  • Numbers of pure B cell clones consistently declined when LPS was present, while the same treatment increased numbers of pure mDC colonies.
  • PaIn 3 CSK 4 also enhanced production of colonies with pure mDC, but did not alter the production of CD19 + B cell clones.
  • the results of these clonal assays concur with those obtained with serum-free, stromal-cell free bulk cultures (FIGS. 6 A & 6D).
  • RT-PCR was then used to evaluate CLP 24 h after stimulation with TLR ligands (FIG. 14).
  • transcripts corresponding to GM-CSF receptors increased with stimulation.
  • Reductions were recorded in the EBF, E12 and RAG-I transcription factors required for lymphopoiesis, in parallel with increases in M-CSF receptor, but changes in three others, PU.1, E47 and Pax-5, were not remarkable.
  • the C/EBP ⁇ transcription factor actually declined after TLR ligation.
  • lymphoid biased progenitors can be driven to a DC fate by the MyD88-dependent TLR signals. Even though CLP express little TLR4/MD-2, LPS alters their differentiation with sufficient amounts of CD 14. TLR signals suppress B lymphopoiesis and reveal the latent myeloid potential of lymphoid biased progenitors.
  • hematopoietic progenitors within bone marrow are directly and quickly affected by exposure to this TLR ligand. Changes in hematopoietic cells in vivo resemble the patterns of differentiation seen under highly defined conditions of culture.
  • HSCs hematopoietic stems cells
  • lymphoid lineage cells can be experimentally converted to macrophages (Kondo et ah, 2000; Iwasaki-Arai et ah, 2003; Xie et ah, 2004).
  • plasmacytoid DCs can convert to myeloid DCs during viral infection (zuniga et ah, 2004).
  • a degree of lineage plasticity could provide a means to respond to microbial/viral products.
  • TLR signals direct hematopoietic cells to a particular fate and obviate the need for normal environmental cytokines cues.
  • Stem/progenitors from MyD88-deficient mice were unresponsive to two TLR ligands, so at least some of the previously described intracellular TLR signaling pathways are used.
  • the MyD 88 -independent TRIF/TICAM pathway which contributes to production of type I IFN (Ueda et ah, 2004; Ueda et ah, 2005), might not be important to the responses observed here.
  • TLR stimulation of stem cells depressed SCL and GATA2 transcripts, while only slightly changing PU.1, but the inventors were surprised to find declines in the C/EBP ⁇ transcription factor that can drive macrophage differentiation (Rosmarin et al., 2l)U->; Xie et al., 20U4). Many of the other transcription factor changes were consistent with increased myeloid differentiation. The inventors considered the possibility that TLR ligands might stimulate hematopoietic cells to make their own factors. However, addition of neutralizing antibodies to M-CSF, GM-CSF, or TNF ⁇ provided no evidence for autocrine stimulation. Further experiments are required to exclude the potential contribution of other cytokines.
  • TLR ligands could simultaneously suppress individual progenitors that are inherently biased for lymphopoiesis while stimulating those destined to produce DCs.
  • single progenitors could be "reprogrammed” to adopt different fates as a result of TLR stimulation (Xie et al, 2004).
  • HSCs divide infrequently under normal circumstances, and retention of their unique potential for self-renewal may require residence in specialized niches near the endosteal surface (Zhang et al, 2003). Such an environment could protect the majority of stem cells from systemic events that would have potentially deleterious effects. An additional expectation is that stem cells express only those receptors needed to maintain their quiescence or allow them to actively differentiate as needed to replenish blood cell populations. Therefore, finding that functional TLRs and associated molecules are present at the stem cell stage was unexpected and raises the possibility that TLR ligands influence numbers and characteristics of stem cells in treated animals. Repeated infections could theoretically exhaust self-renewal potential or have other long-term consequences for the stem cell pool. Consequently, protective mechanisms may have evolved to block this response.
  • TLR4 signaling Several negative regulators for TLR signaling have been reported that might work in a cell type-dependent manner (Liew et al, 2005). Furthermore, the RP105/MD-1 complex can be a negative regulator of TLR4 signaling on macrophages (Divanovic et al, 2005). It will therefore be important to learn if signals delivered via inhibitory molecules influence stem cell behavior. On the other hand, recognition that functional TLRs are expressed on stem/progenitors may suggest new ways to manipulate their activity for therapeutic purposes.
  • LPS injections depleted B lineage lymphocytes from bone marrow, as previously described by others (Ueda et al, 2004), and there were corresponding increases in macrophages and DCs. Multiple mechanisms may account for these changes but they are consistent with the responses of highly purified progenitors in defined culture conditions.
  • the TLR4/MD-2 complex undergoes a rapid change on interaction with LPS such that staining with the MTS510 mAb is abolished (Akashi et al, 2003).
  • the inventors exploited this response to learn that injected LPS diffuses into the bone marrow cavity and engages the receptors of stem cells/progenitors.
  • the innate immune system could use this mechanism to sense danger represented by inflamed or remodeled tissues (Seong and Matzinger, 2004) 7 .
  • the inventors are not aware of published descriptions of hematopoietic maturational defects in TLR gene targeted mice, but this could reflect functional redundancy among TLRs.
  • TLRs may have developmental as well as immune roles that are highly conserved. Indeed, sel£7non-self discrimination may begin at the level of hematopoietic stem/progenitors, with TLRs instructing them to replenish the innate immune system.
  • Bone marrow transplantation experiments were conducted to learn how hematopoietic progenitor cells of MyD88 "A mice function relative to those of normal mice. Bone marrow from MyD88 ⁇ " mice was transplanted along with bone marrow from MyD88 +/+ mice (2 x 10 6 cells total) in a 1:1 ratio into C57BL/6 (Ly5.1) mice that had been given a lethal dose of irradiation (650 R ⁇ 2). The degree of chimerism was determined by flow cytometry. Three months after the transplantation, most of the blood producing cells in the recipient bone marrow derived from the MyD88 " " cells (FIG. 16).
  • thymocytes and peripheral bood granulocytes were preferentially produced by MyD88 "A cells.
  • the percentage of MyD88 "7" lymphocytes in the spleen was closer to a 1:1 ratio, possibly because lymphocytes have long half lives, and their survival could partially depend on effective TLR signaling.
  • lympho-hematopoietic cells respond to stimulation of TLR2 and TLR4 with lipopeptide and LPS, respectively.
  • the findings were extended by showing that the cells express and utilize TLR9, a receptor for viruses and the ligand CpG ODN. Exposure of lymphoid progenitors to CpG ODN in vivo or in culture redirected them to become dendritic cells rather than lymphocytes.
  • FIG. 17A The B lymphopoiesis was almost completely abolished in cells from acutely infected mice, while dendritic cell formation was very strongly favored. This was also apparent in terms of yield per input progenitor (FIG. 17B), while no abnormalities were found in CLP taken from animals with latent infections (FIG. 17C).
  • the same disease model was then used with TLR9 gene targeted mice. Lymphoid and dendritic cells in bone marrow of mutant animals were refractory to acute infection. Furthermore, priming of lymphoid progenitors to dendritic fates was negligible when the TLR9 receptor was absent.
  • TLR9 hematopoietic cells express functional , TLR9, and that the receptor mediates responses to acute viral infection.
  • Therapeutic manipulation of TLR signaling may be advantageous for protecting stem cells in some circumstances and boosting replenishment of the innate immune system.
  • compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. AU such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims. X. References

Abstract

La découvert de récepteurs du type Toll (TLR) sur la surface des cellules hématopoïétiques donne lieu à de nouvelles méthodes pour la stimulation et la différenciation de diverses classes de cellules progénitrices. Les agonistes de TLR2 et de TLR4 (ligands naturels, mimétiques, anticorps) sont particulièrement utiles dans ces méthodes. Ces cellules peuvent être isolées et utilisées pour diverses finalités notamment la régénération et le greffage tissulaire. Les antagonistes de la voie TLR peuvent servir à protéger des cellules contre différentes attaques, notamment chimiothérapiques et radiothérapiques, l'infection aiguë et chronique et la transplantation en inhibant l'activation et la différenciation. Les antagonistes des voies TLR2, TLR4 et TLR9 (TLR soluble, mimétiques, anticorps) sont particulièrement utiles dans ces méthodes. Des cellules peuvent être isolées et utilisées pour diverses finalités notamment la transplantation.
PCT/US2006/037853 2005-09-30 2006-09-29 Regulation de recepteurs du type toll sur des cellules souches WO2007041218A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2006297259A AU2006297259A1 (en) 2005-09-30 2006-09-29 Regulation of toll-like receptors on stem cells
JP2008533600A JP2009509540A (ja) 2005-09-30 2006-09-29 幹細胞におけるＴｏｌｌ様受容体の調節
EP06825199A EP1929032A4 (fr) 2005-09-30 2006-09-29 Regulation de recepteurs du type toll sur des cellules souches
CA002624087A CA2624087A1 (fr) 2005-09-30 2006-09-29 Regulation de recepteurs du type toll sur des cellules souches

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72217405P 2005-09-30 2005-09-30
US60/722,174 2005-09-30
US80635106P 2006-06-30 2006-06-30
US60/806,351 2006-06-30

Publications (2)

Publication Number Publication Date
WO2007041218A2 true WO2007041218A2 (fr) 2007-04-12
WO2007041218A3 WO2007041218A3 (fr) 2009-05-07

Family

ID=37906703

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/037853 WO2007041218A2 (fr) 2005-09-30 2006-09-29 Regulation de recepteurs du type toll sur des cellules souches

Country Status (6)

Country Link
US (1) US7592003B2 (fr)
EP (1) EP1929032A4 (fr)
JP (1) JP2009509540A (fr)
AU (1) AU2006297259A1 (fr)
CA (1) CA2624087A1 (fr)
WO (1) WO2007041218A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011041478A1 (fr) * 2009-10-02 2011-04-07 Baxter International Inc. Cellules souches hématopoïétiques destinées à être utilisées dans le traitement d'une lésion rénale
WO2012096917A1 (fr) * 2011-01-10 2012-07-19 Novimmune S.A. Anticorps anti-tlr4 et leurs procédés d'utilisation
WO2013053719A3 (fr) * 2011-10-11 2013-06-27 Aliophtha Ag Régulation de l'expression d'un récepteur par l'intermédiaire de l'administration de facteurs de transcription artificiels
US8730555B2 (en) 2007-12-06 2014-05-20 Liquavista B.V. Electrowetting display having controlled fluid motion
US9487778B2 (en) 2011-03-03 2016-11-08 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
US9796979B2 (en) 2011-03-03 2017-10-24 Quark Pharmaceuticals Inc. Oligonucleotide modulators of the toll-like receptor pathway

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
NZ600143A (en) * 2007-02-23 2013-01-25 Baylor Res Inst Therapeutic applications of activation of human antigen-presenting cells through dectin-1
WO2009015107A1 (fr) * 2007-07-20 2009-01-29 Yeda Research And Development Co. Ltd. Modulation de récepteurs de type toll pour contrôler la neurogenèse
WO2012068355A2 (fr) 2010-11-18 2012-05-24 Tufts Medical Center, Inc. Traitement d'un anévrisme aortique en modulant les récepteurs de type toll
CA2828002A1 (fr) * 2011-03-03 2012-09-07 Quark Pharmaceuticals, Inc. Compositions et procedes pour traiter des maladies et des lesions pulmonaires
WO2013169382A1 (fr) * 2012-05-07 2013-11-14 DePuy Synthes Products, LLC Méthodes et dispositifs pour le traitement d'une maladie des disques intervertébraux
KR101482999B1 (ko) 2013-06-17 2015-01-14 순천향대학교 산학협력단 톨-유사 수용체(tlr)에 의해 유도되는 trif-의존성 신호전달 경로의 억제제로서의 (e)-1-(2-(2-니트로 비닐)페닐)피롤리딘(nvpp)을 유효성분으로 포함하는 항염증제
WO2015175957A1 (fr) 2014-05-16 2015-11-19 Baylor Research Institute Méthodes et compositions de traitement de maladies auto-immunes et inflammatoires
JP2019069905A (ja) * 2016-02-29 2019-05-09 国立大学法人大阪大学 組織損傷治療剤
CN117045799B (zh) * 2023-10-12 2024-01-09 细胞生态海河实验室 激动或抑制Toll样受体8的物质在制备影响人红细胞发育的药物或试剂中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072347A1 (en) 2001-07-27 2004-04-15 Gerold Schuler Generation of fully mature and stable dendritic cells from leukaphereses products for clinical applications
EP1279728A1 (fr) 2001-07-27 2003-01-29 Schuler, Gerold Generation, à partir de produits de Leukapherese, de cellules dendritiques complètement matures et stables destinées à des utilisations cliniques
US20040259790A1 (en) * 2003-01-30 2004-12-23 Bali Pulendran Methods for identifying and administering agents that bias the immune response via dendritic cells
US20050163764A1 (en) 2003-09-22 2005-07-28 Yale University Treatment with agonists of toll-like receptors
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
BRPI0506916A (pt) * 2004-01-16 2007-05-29 Cbio Ltd modulação da chaperonina 10 da secreção de citocina e de quimiocina que pode ser induzida pelo receptor similar a toll

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1929032A4 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8730555B2 (en) 2007-12-06 2014-05-20 Liquavista B.V. Electrowetting display having controlled fluid motion
WO2011041478A1 (fr) * 2009-10-02 2011-04-07 Baxter International Inc. Cellules souches hématopoïétiques destinées à être utilisées dans le traitement d'une lésion rénale
WO2012096917A1 (fr) * 2011-01-10 2012-07-19 Novimmune S.A. Anticorps anti-tlr4 et leurs procédés d'utilisation
US10421809B2 (en) 2011-01-10 2019-09-24 Novimmune Sa Anti-TLR4 antibodies and uses thereof
US9487778B2 (en) 2011-03-03 2016-11-08 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
US9796979B2 (en) 2011-03-03 2017-10-24 Quark Pharmaceuticals Inc. Oligonucleotide modulators of the toll-like receptor pathway
WO2013053719A3 (fr) * 2011-10-11 2013-06-27 Aliophtha Ag Régulation de l'expression d'un récepteur par l'intermédiaire de l'administration de facteurs de transcription artificiels
CN103998609A (zh) * 2011-10-11 2014-08-20 阿里奥弗塔股份公司 通过递送人工转录因子调节受体表达

Also Published As

Publication number Publication date
EP1929032A2 (fr) 2008-06-11
JP2009509540A (ja) 2009-03-12
WO2007041218A3 (fr) 2009-05-07
AU2006297259A1 (en) 2007-04-12
US7592003B2 (en) 2009-09-22
US20070087408A1 (en) 2007-04-19
EP1929032A4 (fr) 2009-11-04
CA2624087A1 (fr) 2007-04-12

Similar Documents

Publication Publication Date Title
US7592003B2 (en) Regulation of toll-like receptors on stem cells
Caligiuri Human natural killer cells
Schäkel et al. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells
Welner et al. Lymphoid precursors are directed to produce dendritic cells as a result of TLR9 ligation during herpes infection
MacDonald et al. Functional CD40 ligand is expressed by T cells in rheumatoid arthritis.
Smith et al. Ly-49 multigene family expressed by IL-2-activated NK cells.
US6555318B2 (en) Method for identification of cell growth or differentiation factors
Zhang et al. Human mast cells express stem cell factor
Moretta et al. Human NK cells and their receptors
US8383404B2 (en) Hematopoietic stem cell identification and isolation
WO1997021802A9 (fr) Nouvelles populations cellulaires embryonnaires et precedes permettant d'isoler lesdites populations
JP2000516466A (ja) Ｗｎｔポリペプチドについての使用
CZ307995A3 (en) Ligands for flt3 receptors
JPH11514879A (ja) 原始ヒト幹細胞を有するＭｐ１リガンドの使用法
Bazil et al. A monoclonal antibody recognizing CD43 (leukosialin) initiates apoptosis of human hematopoietic progenitor cells but not stem cells
Borges et al. Potent stimulation of the innate immune system by a Leishmania brasiliensis recombinant protein
US20040166108A1 (en) Antibodies specific for plasmacytoid dendritic cells
Dumont Stimulation of murine T cells via the Ly-6C antigen: lack of proliferative response in aberrant T cells from lpr/lpr and gld/gld mice despite high Ly-6C antigen expression.
Windhagen et al. Human polymorphonuclear neutrophils express a B7‐1‐like molecule
US9750767B2 (en) IL-18 inhibition for promotion of early hematopoietic progenitor expansion
Cowan et al. Tolerance induction post in utero stem cell transplantation
Kalis Regulation of B lymphopoiesis in rabbit
RU2220979C2 (ru) ПОЛИПЕПТИД ЛИГАНДА flt3 (ВАРИАНТЫ), ПОЛИНУКЛЕОТИД(ВАРИАНТЫ), ЭКСПРЕССИРУЮЩИЙ ВЕКТОР(ВАРИАНТЫ), ЛИНИЯ КЛЕТОК СНО (ВАРИАНТЫ), СПОСОБ ПРОДУЦИРОВАНИЯ ПОЛИПЕПТИДА ЛИГАНДА flt3 (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ)
Morelli et al. Triggering of the cytotoxic activity of murine natural killer and lymphokine-activated killer cells through the NK2. 1 antigen.
Ferreira Naive T cell survival and homeostasis analysis of monoclonal and polyclonal T cell populations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006825199

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006297259

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2624087

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008533600

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006297259

Country of ref document: AU

Date of ref document: 20060929

Kind code of ref document: A